EP4038103A1 - Dimerizing agent regulated immunoreceptor complexes - Google Patents
Dimerizing agent regulated immunoreceptor complexesInfo
- Publication number
- EP4038103A1 EP4038103A1 EP20873077.0A EP20873077A EP4038103A1 EP 4038103 A1 EP4038103 A1 EP 4038103A1 EP 20873077 A EP20873077 A EP 20873077A EP 4038103 A1 EP4038103 A1 EP 4038103A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- domain
- cell
- antigen
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001105 regulatory effect Effects 0.000 title description 6
- 230000000447 dimerizing effect Effects 0.000 title description 4
- 108091007433 antigens Proteins 0.000 claims abstract description 157
- 239000000427 antigen Substances 0.000 claims abstract description 143
- 102000036639 antigens Human genes 0.000 claims abstract description 143
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 76
- 201000011510 cancer Diseases 0.000 claims abstract description 51
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 3
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims abstract description 3
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims abstract description 3
- 230000007813 immunodeficiency Effects 0.000 claims abstract description 3
- 208000024891 symptom Diseases 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 434
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 408
- 229920001184 polypeptide Polymers 0.000 claims description 406
- 230000027455 binding Effects 0.000 claims description 253
- 210000004027 cell Anatomy 0.000 claims description 205
- 230000000139 costimulatory effect Effects 0.000 claims description 155
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 239000012634 fragment Substances 0.000 claims description 92
- 102000004169 proteins and genes Human genes 0.000 claims description 92
- 102000001301 EGF receptor Human genes 0.000 claims description 70
- 108060006698 EGF receptor Proteins 0.000 claims description 70
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 70
- 230000004927 fusion Effects 0.000 claims description 60
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 58
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 58
- 102100038078 CD276 antigen Human genes 0.000 claims description 56
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 54
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 54
- 102100030886 Complement receptor type 1 Human genes 0.000 claims description 49
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims description 49
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 48
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 48
- 102000008229 Toll-like receptor 1 Human genes 0.000 claims description 46
- 108010060889 Toll-like receptor 1 Proteins 0.000 claims description 46
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 45
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 44
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 44
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 44
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 44
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 42
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 42
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 42
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims description 42
- 102100038083 Endosialin Human genes 0.000 claims description 42
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 42
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 claims description 42
- 101710178381 Melanoma antigen preferentially expressed in tumors Proteins 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 40
- -1 CD44v7/8 Proteins 0.000 claims description 36
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 36
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 36
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 36
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 36
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 30
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 29
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 claims description 28
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 28
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 28
- 108700012439 CA9 Proteins 0.000 claims description 28
- 101710185679 CD276 antigen Proteins 0.000 claims description 28
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 28
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 28
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 28
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 28
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 28
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 claims description 28
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 28
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 28
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 28
- 102000010956 Glypican Human genes 0.000 claims description 28
- 108050001154 Glypican Proteins 0.000 claims description 28
- 108050007237 Glypican-3 Proteins 0.000 claims description 28
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 28
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 28
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims description 28
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 28
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 28
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 28
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 28
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 28
- 102000043129 MHC class I family Human genes 0.000 claims description 28
- 108091054437 MHC class I family Proteins 0.000 claims description 28
- 102000003735 Mesothelin Human genes 0.000 claims description 28
- 108090000015 Mesothelin Proteins 0.000 claims description 28
- 102100023123 Mucin-16 Human genes 0.000 claims description 28
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 28
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 28
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 claims description 28
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims description 28
- 108050005093 Placenta-specific protein 1 Proteins 0.000 claims description 28
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims description 28
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 28
- 102100037686 Protein SSX2 Human genes 0.000 claims description 28
- 101710149284 Protein SSX2 Proteins 0.000 claims description 28
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 28
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 28
- 101710190034 Trophoblast glycoprotein Proteins 0.000 claims description 28
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 28
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 28
- 208000008383 Wilms tumor Diseases 0.000 claims description 28
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 28
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 28
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 28
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims description 28
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 28
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 26
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 26
- 230000004913 activation Effects 0.000 claims description 24
- 239000000539 dimer Substances 0.000 claims description 24
- 239000013638 trimer Substances 0.000 claims description 24
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 23
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 23
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 23
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 23
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 23
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 23
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 23
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 23
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 23
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 23
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 23
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 23
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 23
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 23
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 23
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 23
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 23
- 241001416177 Vicugna pacos Species 0.000 claims description 23
- 102100027207 CD27 antigen Human genes 0.000 claims description 22
- 101150013553 CD40 gene Proteins 0.000 claims description 22
- 102100035793 CD83 antigen Human genes 0.000 claims description 22
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 22
- 101710157460 Hematopoietic cell signal transducer Proteins 0.000 claims description 22
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 22
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 22
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 22
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 22
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 22
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 22
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 22
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 22
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 22
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 22
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 22
- 101710192730 Linker for activation of T-cells family member 1 Proteins 0.000 claims description 22
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 22
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 22
- 102100029453 T-cell receptor-associated transmembrane adapter 1 Human genes 0.000 claims description 22
- 101710113863 T-cell receptor-associated transmembrane adapter 1 Proteins 0.000 claims description 22
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 22
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 22
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 22
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 22
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 21
- 238000003776 cleavage reaction Methods 0.000 claims description 20
- 230000007017 scission Effects 0.000 claims description 20
- 229960002930 sirolimus Drugs 0.000 claims description 20
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 17
- 102000003886 Glycoproteins Human genes 0.000 claims description 16
- 108090000288 Glycoproteins Proteins 0.000 claims description 16
- ZHYGVVKSAGDVDY-QQQXYHJWSA-N 7-o-demethyl cypher Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](O)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 ZHYGVVKSAGDVDY-QQQXYHJWSA-N 0.000 claims description 15
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims description 15
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 15
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 15
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 15
- 229960005167 everolimus Drugs 0.000 claims description 15
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 15
- 229960005330 pimecrolimus Drugs 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 229960001302 ridaforolimus Drugs 0.000 claims description 15
- 229960001967 tacrolimus Drugs 0.000 claims description 15
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 15
- 229960000235 temsirolimus Drugs 0.000 claims description 15
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 15
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims description 15
- 229950007775 umirolimus Drugs 0.000 claims description 15
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 15
- 229950009819 zotarolimus Drugs 0.000 claims description 15
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 14
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 14
- 102000012440 Acetylcholinesterase Human genes 0.000 claims description 14
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 14
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 14
- 102100032912 CD44 antigen Human genes 0.000 claims description 14
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 14
- 102100025221 CD70 antigen Human genes 0.000 claims description 14
- 101710120600 Cancer/testis antigen 1 Proteins 0.000 claims description 14
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 14
- 101710120595 Cancer/testis antigen 2 Proteins 0.000 claims description 14
- 102000014914 Carrier Proteins Human genes 0.000 claims description 14
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 14
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 14
- 102300047802 Cutaneous T-cell lymphoma-associated antigen 1 isoform 1 Human genes 0.000 claims description 14
- 101710144543 Endosialin Proteins 0.000 claims description 14
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 14
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 14
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 14
- 101600098482 Homo sapiens Cutaneous T-cell lymphoma-associated antigen 1 (isoform 1) Proteins 0.000 claims description 14
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 14
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 14
- 101001005725 Homo sapiens Melanoma-associated antigen 10 Proteins 0.000 claims description 14
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 14
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 claims description 14
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 14
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 claims description 14
- 101000607316 Homo sapiens UL-16 binding protein 5 Proteins 0.000 claims description 14
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 claims description 14
- 101000607318 Homo sapiens UL16-binding protein 3 Proteins 0.000 claims description 14
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 14
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 14
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 14
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 14
- 102100025049 Melanoma-associated antigen 10 Human genes 0.000 claims description 14
- 102100034256 Mucin-1 Human genes 0.000 claims description 14
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 14
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 claims description 14
- 108050009432 Plexin domain-containing protein 1 Proteins 0.000 claims description 14
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 claims description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 14
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 claims description 14
- 108010002687 Survivin Proteins 0.000 claims description 14
- 102100040010 UL-16 binding protein 5 Human genes 0.000 claims description 14
- 102100039989 UL16-binding protein 2 Human genes 0.000 claims description 14
- 102100040011 UL16-binding protein 3 Human genes 0.000 claims description 14
- 102100040013 UL16-binding protein 6 Human genes 0.000 claims description 14
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 14
- 108091008324 binding proteins Proteins 0.000 claims description 14
- 230000001605 fetal effect Effects 0.000 claims description 14
- 210000002950 fibroblast Anatomy 0.000 claims description 14
- 102000006815 folate receptor Human genes 0.000 claims description 14
- 108020005243 folate receptor Proteins 0.000 claims description 14
- 150000002270 gangliosides Chemical class 0.000 claims description 14
- 102000006495 integrins Human genes 0.000 claims description 14
- 108010044426 integrins Proteins 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 14
- 239000010445 mica Substances 0.000 claims description 14
- 229910052618 mica group Inorganic materials 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 12
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 12
- 239000012642 immune effector Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 9
- 102100040120 Prominin-1 Human genes 0.000 claims description 9
- 102100035721 Syndecan-1 Human genes 0.000 claims description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 8
- 241000214054 Equine rhinitis A virus Species 0.000 claims description 8
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 8
- 241001672814 Porcine teschovirus 1 Species 0.000 claims description 8
- 241001648840 Thosea asigna virus Species 0.000 claims description 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 206010003445 Ascites Diseases 0.000 claims description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims description 6
- 208000002151 Pleural effusion Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
- 210000001165 lymph node Anatomy 0.000 claims description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 210000001541 thymus gland Anatomy 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 4
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 241001196954 Theilovirus Species 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 240000007019 Oxalis corniculata Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 208000010094 Visna Diseases 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 11
- 102000016200 MART-1 Antigen Human genes 0.000 claims 7
- 101150042088 UL16 gene Proteins 0.000 claims 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 7
- 230000011664 signaling Effects 0.000 abstract description 22
- 230000001976 improved effect Effects 0.000 abstract description 4
- 238000002659 cell therapy Methods 0.000 abstract description 3
- 230000008685 targeting Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 49
- 108091008874 T cell receptors Proteins 0.000 description 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 21
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 12
- 125000005647 linker group Chemical group 0.000 description 12
- 230000006870 function Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004068 intracellular signaling Effects 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 238000011467 adoptive cell therapy Methods 0.000 description 5
- 206010052015 cytokine release syndrome Diseases 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 101150002618 TCRP gene Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JLIDBLDQVAYHNE-LXGGSRJLSA-N 2-cis-abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\C1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-LXGGSRJLSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101100446641 Homo sapiens FKBP1A gene Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940125385 biologic drug Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- PSLNMAUXUJLNBW-OUPLBGLBSA-N dnc008570 Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](C=2C3=CC=CC(C)=C3NC=2)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)[C@H](O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)[C@@H](O)C1 PSLNMAUXUJLNBW-OUPLBGLBSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 102000055209 human FKBP1A Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102200015453 rs121912293 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present disclosure relates to improved adoptive cell therapies. More particularly, the disclosure relates to improved chemically regulated signaling molecules, cells, and methods of using the same for modulating spatial and temporal control of cellular signal initiation and downstream responses during adoptive immunotherapy.
- Cancer The global burden of cancer doubled between 1975 and 2000. Cancer is the second leading cause of morbidity and mortality worldwide, with approximately 14.1 million new cases and 8.2 million cancer related deaths in 2012.
- the most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, endometrial cancer, leukemia, and pancreatic cancer.
- the number of new cancer cases is projected to rise to 22 million within the next two decades.
- adoptive cell therapies have the potential to execute unique therapeutic tasks owing to their myriad sensory and response programs and increasingly defined mechanisms of genetic control.
- cells need to be outfitted with machinery for sensing and integrating chemical and/or biological information associated with local physiological environments.
- the present disclosure generally relates, in part, to dimerizing agent regulated immunoreceptor complexes (DARICs) that can both recognize a target antigen and recruit and activate a T cell receptor (TCR) signaling complex, polynucleotides and polypeptides encoding the same, compositions thereof, and methods of making and using the same to treat cancer.
- DARICs dimerizing agent regulated immunoreceptor complexes
- TCR T cell receptor
- a non-natural cell comprises: a first polypeptide comprising: a first binding domain that binds a target antigen expressed on a cancer cell; an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; and a first costimulatory domain; and a second polypeptide comprising: a second binding domain that binds to CD3e, CD35 or CD3y; an FRB multimerization domain polypeptide or variant thereof; and a second transmembrane domain; wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.
- the FKBP multimerization domain polypeptide is FKBP 12.
- the FRB multimerization domain polypeptide is FRB
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the first binding domain comprises an antibody or antigen binding fragment thereof.
- the first binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv,
- scFv single-domain antibody
- dsFv single-domain antibody
- the first binding domain comprises an scFv.
- the first binding domain comprises a VHH antibody.
- the first binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lectin like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40
- the first binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- the first transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the first transmembrane domain is a CD4 transmembrane domain.
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARDll), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX- Activation Protein 10 (DAP 10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 Toll
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the first costimulatory domain is a LCK polypeptide.
- the first polypeptide comprises the first binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide, a CD8a transmembrane domain; and a LCK polypeptide.
- the second binding domain comprises an antibody or antigen binding fragment thereof that binds CD3e, CD35 or CD3y.
- the second binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody), that binds CD3e.
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- the second binding domain comprises an scFv that binds CD3e, CD35 or CD3y.
- the second binding domain comprises a VHH antibody that binds CD3e, CD35 or CD3y.
- the second transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the second transmembrane domain is a CD8a transmembrane domain.
- the second polypeptide further comprises a second costimulatory domain.
- the costimulatory domain of the second polypeptide is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD 11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAPIO), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2,
- TLR1 Toll-like receptor 1
- TLR2 TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9
- TNFRS14 TNFRS18
- TNRFS25 T cell receptor associated protein kinase 70
- ZAP70 zeta chain of T cell receptor associated protein kinase 70
- the costimulatory domain of the second polypeptide is a costimulatory domain isolated from 0X40 or TNFR2.
- a non-natural cell comprises: a polypeptide complex that comprises a first polypeptide comprising: a first binding domain that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide or variant thereof; a first transmembrane domain; and a first costimulatory domain; a second polypeptide comprising: a second binding domain that binds to CD3e, CD35 or CD3y; an FRB multimerization domain polypeptide or variant thereof; and a second transmembrane domain; and a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.
- the FKBP multimerization domain polypeptide is FKBP12.
- the FRB multimerization domain polypeptide is FRB T2098L.
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the first binding domain comprises an antibody or antigen binding fragment thereof.
- the first binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- the first binding domain comprises an scFv.
- the first binding domain comprises a VHH antibody.
- the first binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lectin like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40
- the first binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- the first transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the first transmembrane domain is a CD4 transmembrane domain.
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARDll), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX- Activation Protein 10 (DAP 10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 Toll
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the first costimulatory domain is a LCK polypeptide.
- the first polypeptide comprises the first binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain; and a LCK polypeptide.
- the second binding domain comprises an antibody or antigen binding fragment thereof that binds CD3e, CD35 or CD3y.
- the second binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody), that binds CD3e.
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- the second binding domain comprises an scFv that binds CD3e, CD35 or CD3y.
- the second binding domain comprises a VHH antibody that binds CD3e, CD35 or CD3y.
- the second transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the second transmembrane domain is a CD8a transmembrane domain.
- the second polypeptide further comprises a second costimulatory domain.
- the costimulatory domain of the second polypeptide is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD 11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAPIO), Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 Toll-like
- the costimulatory domain of the second polypeptide is a costimulatory domain isolated from 0X40 or TNFR2.
- the cell is a hematopoietic cell.
- the cell is a T cell.
- the cell is a CD3+, CD4+, and/or CD8+ cell.
- the cell is an immune effector cell.
- the cell is a cytotoxic T lymphocytes (CTLs), a tumor infiltrating lymphocytes (TILs), or a helper T cell.
- CTLs cytotoxic T lymphocytes
- TILs tumor infiltrating lymphocytes
- helper T cell a helper T cell.
- the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
- NK natural killer
- NKT natural killer T
- the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
- the FRB multimerization domain polypeptide and the FKBP multimerization domain polypeptide localize extracellularly when the first polypeptide and the second polypeptide are expressed.
- a non-natural cell comprises: a first polypeptide comprising: a binding domain that binds a target antigen expressed on a cancer cell; an FKBP multimerization domain polypeptide or variant thereof; a transmembrane domain; and a costimulatory domain; and a second polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a linker polypeptide, and a CD3e, CD35 or CD3y polypeptide; wherein a bridging factor promotes the formation of a polypeptide complex on the non-natural cell surface with the bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.
- the FKBP multimerization domain polypeptide is FKBP 12.
- the FRB multimerization domain polypeptide is FRB T2098L.
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the binding domain comprises an antibody or antigen binding fragment thereof.
- the binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv,
- scFv single-domain antibody
- dsFv single-domain antibody
- the binding domain comprises an scFv.
- the binding domain comprises a VHH antibody.
- the binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b,
- FRa alpha folate receptor
- BCMA B cell maturation antigen
- B7-H3 CD276
- CAIX carbonic anhydrase IX
- the binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- the transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the transmembrane domain is a CD4 transmembrane domain.
- the costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARDll), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX- Activation Protein 10 (DAP 10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 Toll-
- the costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the costimulatory domain is a LCK polypeptide.
- the costimulatory domain is a costimulatory domain isolated from 0X40 or TNFR2.
- the first polypeptide comprises the binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain; and optionally, a LCK polypeptide.
- a fusion polypeptide comprises: a first polypeptide comprising: a first binding domain that binds a target antigen expressed on a cancer cell; an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; and a first costimulatory domain; a polypeptide cleavage signal; and a second polypeptide comprising: a second binding domain that binds to CD3e, CD35 or CD3y; an FRB multimerization domain polypeptide or variant thereof; and a second transmembrane domain.
- a fusion polypeptide comprises from N-terminus to C- terminus: a first polypeptide comprising: a first binding domain that binds a target antigen expressed on a cancer cell; an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; and a first costimulatory domain; a polypeptide cleavage signal; and a second polypeptide comprising: a second binding domain that binds to CD3e, CD35 or CD3y; an FRB multimerization domain polypeptide or variant thereof; and a second transmembrane domain.
- the FKBP multimerization domain polypeptide is FKBP12.
- the FRB multimerization domain polypeptide is FRB T2098L.
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the first binding domain comprises an antibody or antigen binding fragment thereof.
- the first binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- Fab3 bispecific
- the first binding domain comprises an scFv. In additional embodiments, the first binding domain comprises a VHH antibody.
- the first binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lectin like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40
- the first binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33,
- the first transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the first transmembrane domain is a CD4 transmembrane domain.
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX- Activation Protein 10 (DAP 10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 Toll
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the first costimulatory domain is a LCK polypeptide.
- the first polypeptide comprises the first binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain; and a LCK polypeptide.
- the second binding domain comprises an antibody or antigen binding fragment thereof that binds CD3e, CD35 or CD3y.
- the second binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody), that binds CD3e.
- the second binding domain comprises an scFv that binds CD3e, CD35 or CD3y.
- the second binding domain comprises a VHH antibody that binds CD3e, CD35 or CD3y.
- the second transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the second transmembrane domain is a CD8a transmembrane domain.
- the second polypeptide further comprises a second costimulatory domain.
- the costimulatory domain of the second polypeptide is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD 11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAPIO), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2,
- TLR1 Toll-like receptor 1
- TLR2 TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9
- TNFRS14 TNFRS18
- TNRFS25 T cell receptor associated protein kinase 70
- ZAP70 zeta chain of T cell receptor associated protein kinase 70
- the costimulatory domain of the second polypeptide is a costimulatory domain isolated from 0X40 or TNFR2.
- the polypeptide cleavage signal is a viral self-cleaving polypeptide.
- the polypeptide cleavage signal is a viral self-cleaving 2A polypeptide.
- the polypeptide cleavage signal is a viral self-cleaving polypeptide selected from the group consisting of: a foot-and-mouth disease virus (FMDV) (F2A) peptide, an equine rhinitis A virus (ERAV) (E2A) peptide, a Thosea asigna virus (TaV) (T2A) peptide, a porcine teschovirus-1 (PTV-1) (P2A) peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.
- FMDV foot-and-mouth disease virus
- E2A equine rhinitis A virus
- TaV Thosea asigna virus
- PTV-1 porcine teschovirus-1
- P2A porcine teschovirus-1
- Theilovirus 2A peptide a Theilovirus 2A peptide
- a fusion polypeptide comprises: a first polypeptide comprising: a binding domain that binds a target antigen expressed on a cancer cell; an FKBP multimerization domain polypeptide or variant thereof; a transmembrane domain; and a costimulatory domain; a polypeptide cleavage signal; and a second polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a linker polypeptide, and a CD3e, CD35 or CD3y polypeptide.
- a fusion polypeptide comprises from N-terminus to C- terminus: a first polypeptide comprising: a binding domain that binds a target antigen expressed on a cancer cell; an FKBP multimerization domain polypeptide or variant thereof; a transmembrane domain; and a costimulatory domain; a polypeptide cleavage signal; and a second polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a linker polypeptide, and a CD3e, CD35 or CD3y polypeptide.
- the FKBP multimerization domain polypeptide is FKBP12.
- the FRB multimerization domain polypeptide is FRB T2098L.
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the binding domain comprises an antibody or antigen binding fragment thereof.
- the binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- Fab3 bispecific Fab
- the binding domain comprises an scFv. In other embodiments, the binding domain comprises a VHH antibody.
- the binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b,
- FRa alpha folate receptor
- BCMA B cell maturation antigen
- B7-H3 CD276
- CAIX carbonic anhydrase IX
- the binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a,
- the transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the transmembrane domain is a CD4 transmembrane domain.
- the costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DN AX- Activation Protein 10 (DAP10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 To
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the first costimulatory domain is a LCK polypeptide.
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: 0X40 and TNFR2.
- the first polypeptide comprises the first binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain; and a LCK polypeptide.
- the polypeptide cleavage signal is a viral self-cleaving polypeptide.
- the polypeptide cleavage signal is a viral self-cleaving 2A polypeptide.
- the polypeptide cleavage signal is a viral self-cleaving polypeptide selected from the group consisting of: a foot-and-mouth disease virus (FMDV) (F2A) peptide, an equine rhinitis A virus (ERAV) (E2A) peptide, a Thosea asigna virus (TaV) (T2A) peptide, a porcine teschovirus-1 (PTV-1) (P2A) peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.
- FMDV foot-and-mouth disease virus
- E2A equine rhinitis A virus
- TaV Thosea asigna virus
- PTV-1 porcine teschovirus-1
- P2A porcine teschovirus-1
- Theilovirus 2A peptide a Theilovirus 2A peptide
- a polypeptide complex comprises: a first polypeptide comprising: a first binding domain that binds a target antigen expressed on a cancer cell, an FKBP multimerization domain polypeptide or variant thereof; a first transmembrane domain; and a first costimulatory domain; a second polypeptide comprising: a second binding domain that binds to CD3e, CD35 or CD3y; an FRB multimerization domain polypeptide or variant thereof; and a second transmembrane domain; and a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.
- the FKBP multimerization domain polypeptide is FKBP 12.
- the FRB multimerization domain polypeptide is FRB T2098L.
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the first binding domain comprises an antibody or antigen binding fragment thereof.
- the first binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- Fab3 bispecific
- the first binding domain comprises an scFv.
- the first binding domain comprises a VHH antibody.
- the first binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lectin like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40
- the first binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- the first transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain. In some embodiments, the first transmembrane domain is a CD4 transmembrane domain.
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX- Activation Protein 10 (DAP 10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 Toll
- the first costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the first costimulatory domain is a LCK polypeptide.
- the first polypeptide comprises the first binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain; and a LCK polypeptide.
- the second binding domain comprises an antibody or antigen binding fragment thereof that binds CD3e, CD35 or CD3y.
- the second binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody), that binds CD3e.
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- the second binding domain comprises an scFv that binds CD3e, CD35 or CD3y. In certain embodiments, the second binding domain comprises a VHH antibody that binds CD3e, CD35 or CD3y.
- the second transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the second transmembrane domain is a CD8a transmembrane domain.
- the second polypeptide further comprises a second costimulatory domain.
- the costimulatory domain of the second polypeptide is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD 11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAPIO), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2,
- TLR1 Toll-like receptor 1
- TLR2 TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9
- TNFRS14 TNFRS18
- TNRFS25 T cell receptor associated protein kinase 70
- ZAP70 zeta chain of T cell receptor associated protein kinase 70
- the costimulatory domain of the second polypeptide is a costimulatory domain isolated from 0X40 or TNFR2.
- the cell is a hematopoietic cell.
- the cell is a T cell.
- the cell is a CD3+, CD4+, and/or CD8+ cell.
- the cell is an immune effector cell.
- the cell is a cytotoxic T lymphocytes (CTLs), a tumor infiltrating lymphocytes (TILs), or a helper T cell.
- CTLs cytotoxic T lymphocytes
- TILs tumor infiltrating lymphocytes
- helper T cell a helper T cell.
- the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
- the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
- the FRB multimerization domain polypeptide and the FKBP multimerization domain polypeptide localize extracellularly when of the first polypeptide and the second polypeptide are expressed.
- a polypeptide complex comprises: a first polypeptide comprising: a binding domain that binds a target antigen expressed on a cancer cell, an FKBP multimerization domain polypeptide or variant thereof; a transmembrane domain; and a costimulatory domain; a second polypeptide comprising: an FRB multimerization domain polypeptide or variant thereof; a linker polypeptide; and a CD3e, CD35 or CD3y polypeptide; and a bridging factor associated with and disposed between the multimerization domains of the first and second polypeptides.
- the FKBP multimerization domain polypeptide is FKBP 12.
- the FRB multimerization domain polypeptide is FRB T2098L.
- the bridging factor is selected from the group consisting of: AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the binding domain comprises an antibody or antigen binding fragment thereof.
- the binding domain comprises an antibody or antigen binding fragment thereof selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab dimer
- Fab3 bispecific Fab
- the binding domain comprises an scFv. In further embodiments, the binding domain comprises a VHH antibody.
- the binding domain binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb ⁇ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lectin like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (CTAGE1),
- the binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- the transmembrane domain is a CD8a transmembrane domain or a CD4 transmembrane domain.
- the transmembrane domain is a CD4 transmembrane domain.
- the costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DN AX- Activation Protein 10 (DAP10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
- TLR1 To
- the costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: FYN, LCK, and ZAP70.
- the costimulatory domain is a LCK polypeptide.
- the costimulatory domain is selected from a costimulatory molecule selected from the group consisting of: 0X40 and TNFR2.
- the polypeptide comprises the first binding domain that comprises an scFv or VHH that binds a target antigen expressed on a cancer cell, an FKBP multimerization domain polypeptide, a CD4 transmembrane domain; and a LCK polypeptide.
- the cell is a hematopoietic cell.
- the cell is a T cell.
- the cell is a CD3+, CD4+, and/or CD8+ cell.
- the cell is an immune effector cell.
- the cell is a cytotoxic T lymphocytes (CTLs), a tumor infiltrating lymphocytes (TILs), or a helper T cell.
- CTLs cytotoxic T lymphocytes
- TILs tumor infiltrating lymphocytes
- helper T cell a helper T cell.
- the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
- the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
- the FRB multimerization domain and the FKBP multimerization domain localize extracellularly when of the first polypeptide and the second polypeptide are expressed.
- a polynucleotide encodes a first or second polypeptide or a fusion polypeptide contemplated herein.
- the polynucleotide is a cDNA.
- the polynucleotide is an RNA.
- a vector comprises a polynucleotide contemplated herein.
- the vector is an expression vector.
- the vector is a transposon.
- the vector is a piggyBAC transposon or a Sleeping Beauty transposon.
- the vector is a viral vector.
- the vector is an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes virus vector, a vaccinia virus vector, or a retroviral vector.
- AAV adeno-associated viral
- the retroviral vector is a lentiviral vector.
- the lentiviral vector is selected from the group consisting of: human immunodeficiency virus 1 (HIV-1); human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
- HAV-1 human immunodeficiency virus 1
- HMV-2 human immunodeficiency virus 2
- VMV visna-maedi virus
- CAEV caprine arthritis-encephalitis virus
- EIAV equine infectious anemia virus
- FV feline immunodeficiency virus
- BIV bovine immune deficiency virus
- SIV simian immunodeficiency virus
- a composition comprises a non-natural cell, a fusion polypeptide, a polynucleotide, or a vector contemplated herein.
- a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a non-natural cell, a fusion polypeptide, a polynucleotide, or a vector contemplated herein.
- a method of treating a subject in need thereof comprises administering the subject an effective amount of a composition contemplated herein.
- a method of treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith comprises administering to the subject an effective amount of a composition contemplated herein.
- a method of treating a solid cancer comprises administering to the subject an effective amount of a composition contemplated herein.
- the solid cancer is selected from the group consisting of: lung cancer, squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, or brain cancer.
- the solid cancer is a non-small cell lung carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, or oligodendroglioma.
- a method of treating a hematological malignancy comprises administering to the subject an effective amount of a composition contemplated herein.
- the hematological malignancy is a leukemia, lymphoma, or multiple myeloma.
- the hematological malignancy is acute myelogenous leukemia (AML).
- AML acute myelogenous leukemia
- Figure 1 shows a cartoon of a representative DARIC architecture.
- Figure 2 shows a cartoon of a representative DARIC architecture.
- SEQ ID NOs: 1-5 set forth the amino acid sequences for representative DARIC fusion proteins.
- CAR chimeric antigen receptor
- TCR T cell receptors
- T cells engineered to express a CAR or TCR are lack of spatial and temporal control of T cell activity and/or insufficient activation of T cell signaling pathways. Lack of control over engineered T cell activity can trigger a range of side effects, many of which begin subtly but can rapidly worsen.
- a particularly severe complication is cytokine release syndrome (CRS) or “cytokine storm” where CAR T cells induce massive and potentially fatal cytokine release.
- CRS can produce dangerously high fevers, extreme fatigue, difficulty breathing, and a sharp drop in blood pressure.
- CRS can also produce a second wave of side effects that involve the nervous system, including neurotoxicity, tremors, headaches, confusion, loss of balance, trouble speaking, seizures, and hallucinations.
- Insufficient activation of T cell signaling pathways can result in failure to eradicate a cancer and/or lead to a cancer that becomes refractory to treatment.
- the compositions and methods contemplated herein offer solutions to these and other problems plaguing adoptive cell therapies.
- the disclosure generally relates to improved compositions and methods for regulating the spatial and temporal control of adoptive cell therapies using dimerizing agent regulated immunoreceptor complexes (DARICs) that bind a target antigen and that can recruit and activate a TCR signaling complex.
- DARICs dimerizing agent regulated immunoreceptor complexes
- DARIC compositions and methods contemplated herein provide numerous advantages over CAR T cell and TCR T cell therapies existing in the art, including but not limited to, both spatial and temporal control over immune effector cell signal transduction binding and signaling activities and activating TCR-based signaling pathways without requiring MHC complex recognition.
- DARIC temporal control primes the DARIC machinery for signaling through bridging factor mediated association of a DARIC binding component to a DARIC signaling component.
- DARIC spatial control engages the signaling machinery through recognition of a target antigen by a binding domain of a DARIC signaling component, whereas the binding domain of the DARIC binding component binds a member of a TCR complex.
- DARIC immune effector cells activate TCR signaling when both a target cell expressing the target antigen and a bridging factor are present.
- the disclosure contemplates DARIC components that generate a TCR-based anti-cancer response against cancers that express a target antigen without MHC recognition of the target antigen.
- a DARIC includes a polypeptide (DARIC signaling component) that comprises a binding domain that binds a target antigen expressed on a target cell, a multimerization domain polypeptide or variant thereof, a transmembrane domain, and a costimulatory domain; and a polypeptide (DARIC binding component) that comprises a binding domain that binds CD3e, CD35, or CD3y, a multimerization domain polypeptide or variant thereof, a transmembrane domain; and optionally a costimulatory domain.
- DARIC signaling component that comprises a binding domain that binds a target antigen expressed on a target cell, a multimerization domain polypeptide or variant thereof, a transmembrane domain, and a costimulatory domain
- DARIC binding component that comprises a binding domain that binds CD3e, CD35, or CD3y, a multimerization domain polypeptide or variant thereof, a transmembrane domain
- a DARIC includes a polypeptide (DARIC signaling component) that comprises a binding domain that binds a target antigen expressed on a target cell, a multimerization domain polypeptide or variant thereof, a transmembrane domain, and a costimulatory domain; and a polypeptide (DARIC binding component) that comprises a multimerization domain polypeptide or variant thereof, a linker polypeptide, and a CD3e, CD35, or CD3y polypeptide; and optionally a costimulatory domain.
- DARIC signaling component that comprises a binding domain that binds a target antigen expressed on a target cell, a multimerization domain polypeptide or variant thereof, a transmembrane domain, and a costimulatory domain
- DARIC binding component that comprises a multimerization domain polypeptide or variant thereof, a linker polypeptide, and a CD3e, CD35, or CD3y polypeptide
- the DARIC binding and signaling components associate
- the multimerization domains of the DARIC binding and DARIC signaling components are positioned extracellularly.
- Extracellular position of the multimerization domains provides numerous advantages over intracellular positioning including, but not limited to, more efficient positioning of the binding domain, higher temporal sensitivity to bridging factor regulation, and less toxicity due to ability to use non immunosuppressive doses of particular bridging factors.
- DARIC protein complexes DARIC fusion proteins
- cells comprising polynucleotides encoding DARICs, DARIC binding components, and DARIC signaling components and/or expressing the same; and methods of using the same to treat an immune disorder are contemplated herein.
- Techniques for recombinant (i.e., engineered) DNA, peptide and oligonucleotide synthesis, immunoassays, tissue culture, transformation ( e.g ., electroporation, lipofection), enzymatic reactions, purification and related techniques and procedures may be generally performed as described in various general and more specific references in microbiology, molecular biology, biochemistry, molecular genetics, cell biology, virology and immunology as cited and discussed throughout the present specification. See , e.g.
- the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length ⁇ 15%, ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇ 6%, ⁇ 5%, ⁇ 4%, ⁇ 3%, ⁇ 2%, or ⁇ 1% about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- a range e.g., 1 to 5, about 1 to 5, or about 1 to about 5, refers to each numerical value encompassed by the range.
- the range “1 to 5” is equivalent to the expression 1, 2, 3, 4, 5; or 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0; or 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0.
- the term “substantially” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- “substantially the same” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that produces an effect, e.g., a physiological effect, that is approximately the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- an “antigen (Ag)” refers to a compound, composition, or substance that can stimulate the production of antibodies or a T cell response in an animal, including compositions (such as one that includes a cancer-specific protein) that are injected or absorbed into an animal.
- exemplary antigens include but are not limited to lipids, carbohydrates, polysaccharides, glycoproteins, peptides, or nucleic acids.
- An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous antigens, such as the disclosed antigens.
- target antigen or “target antigen of interest” refers to a molecule expressed on the cell surface of a target cell that a binding domain contemplated herein, is designed to bind.
- the target antigen is an epitope of a polypeptide expressed on the surface of a cancer cell.
- TCR complex refers to a complex formed by the association of CD3 with a TCR.
- a TCR complex can be composed of a CD3y chain, a CD35 chain, two CD3e chains, a homodimer of CD3z chains, a TCRa chain, and a TCRP chain.
- a TCR complex can be composed of a CD3y chain, a CD35 chain, two CD3e chains, a homodimer of CD3z chains, a TCRy chain, and a TCR5 chain.
- a “component of a TCR complex,” as used herein, refers to a TCR chain (i.e., TCRa, TCRp, TCRy or TCR5), a CD3 chain (i.e., CD3y, CD35, CD3e or O ⁇ 3z), or a complex formed by two or more TCR chains or CD3 chains (e.g ., a complex of TCRa and TCRP, a complex of TCRy and TCR5, a complex of CD3e and CD35, a complex of CD3y and CD3e, or a sub-TCR complex of TCRa, TCRP, CD3y, CD35, and two CD3e chains).
- TCR chain i.e., TCRa, TCRp, TCRy or TCR5
- CD3 chain i.e., CD3y, CD35, CD3e or O ⁇ 3z
- a complex formed by two or more TCR chains or CD3 chains e.g ., a complex of T
- binding domain As used herein, the terms, “binding domain,” “extracellular domain,” “antigen binding domain,” “extracellular binding domain,” “extracellular antigen binding domain,” “antigen-specific binding domain,” and “extracellular antigen specific binding domain,” are used interchangeably and provide a polypeptide with the ability to specifically bind to the target antigen of interest.
- the binding domain may be derived either from a natural, synthetic, semi -synthetic, or recombinant source.
- binding affinity or “specifically binds” or “specifically bound” or “specific binding” or “specifically targets” as used herein, describe binding of binding domain to a target antigen at greater binding affinity than background binding.
- a binding domain “specifically binds” to a target antigen, if it binds to or associates with the antigen with an affinity or K a (i.e., an equilibrium association constant of a particular binding interaction with units of 1/M) of, for example, greater than or equal to about 10 5 M 1 .
- a binding domain (or a fusion protein comprising the same) binds to a target with a K a greater than or equal to about 10 6 M 1 , 10 7 M 1 , 10 8 M 1 , 10 9 M 1 , 10 10 M l , 10 11 M 1 , 10 12 M 1 , or 10 13 M 1 .
- “High affinity” binding domains (or single chain fusion proteins thereof) refer to those binding domains with a K a of at least 10 7 M 1 , at least 10 8 M 1 , at least 10 9 M 1 , at least 10 10 M 1 , at least 10 11 M 1 , at least 10 12 M 1 , at least 10 13 M 1 , or greater.
- selectively binds or “selectively bound” or “selectively binding” or “selectively targets” and describe preferential binding of one molecule to a target molecule (on- target binding) in the presence of a plurality of off-target molecules.
- an “antibody” refers to a binding agent that is a polypeptide comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen, such as a lipid, carbohydrate, polysaccharide, glycoprotein, peptide, or nucleic acid containing an antigenic determinant, such as those recognized by an immune cell.
- an antigen such as a lipid, carbohydrate, polysaccharide, glycoprotein, peptide, or nucleic acid containing an antigenic determinant, such as those recognized by an immune cell.
- epitope or “antigenic determinant” refers to the region of an antigen to which a binding agent binds.
- Antibodies include antigen binding fragments thereof, such as a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody) and portions of full length antibodies responsible for antigen binding.
- a Camel Ig such as a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific
- the term also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies), heteroconjugate antibodies (such as, bispecific antibodies) and antigen binding fragments thereof. See also , Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL); Kuby, T, Immunology, 3rdEd., W. H. Freeman & Co., New York, 1997.
- a “linker” or “linker polypeptide” refers to a plurality of amino acid residues between the various polypeptide domains added for appropriate spacing and conformation of the molecule.
- the linker is a variable region linking sequence.
- a “variable region linking sequence,” is an amino acid sequence that connects the VH and VL domains and provides a spacer function compatible with interaction of the two sub-binding domains so that the resulting polypeptide retains a specific binding affinity to the same target molecule as an antibody that comprises the same light and heavy chain variable regions.
- a linker separates one or more heavy or light chain variable domains, hinge domains, multimerization domains, transmembrane domains, costimulatory domains, and/or primary signaling domains.
- linker comprises the following amino acid sequence: GSTSGSGKPGSGEGSTKG (SEQ ID NO: 16) (Cooper etal., Blood, 101(4): 1637-1644 (2003)).
- a “spacer domain,” refers to a polypeptide that separates two domains.
- a spacer domain moves an antigen binding domain away from the effector cell surface to enable proper cell/cell contact, antigen binding and activation (Patel etal, Gene Therapy, 1999; 6: 412-419).
- a spacer domain separates one or more heavy or light chain variable domains, multimerization domains, transmembrane domains, costimulatory domains, and/or primary signaling domains.
- the spacer domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.
- a spacer domain is a portion of an immunoglobulin, including, but not limited to, one or more heavy chain constant regions, e.g, CH2 and CH3.
- the spacer domain can include the amino acid sequence of a naturally occurring immunoglobulin hinge region or an altered immunoglobulin hinge region.
- a “hinge domain,” refers to a polypeptide that plays a role in positioning the antigen binding domain away from the effector cell surface to enable proper cell/cell contact, antigen binding and activation.
- polypeptides may comprise one or more hinge domains between the binding domain and the multimerization domain, between the binding domain and the transmembrane domain (TM), or between the multimerization domain and the transmembrane domain.
- the hinge domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.
- the hinge domain can include the amino acid sequence of a naturally occurring immunoglobulin hinge region or an altered immunoglobulin hinge region.
- a “multimerization domain,” or “multimerization domain polypeptide” as used herein, refers to a polypeptide that preferentially interacts or associates with another different polypeptide directly or via a bridging molecule, e.g., a chemically inducible dimerizer, wherein the interaction of different multimerization domains substantially contributes to or efficiently promotes multimerization (i.e., the formation of a dimer, trimer, or multipartite complex, which may be a homodimer, heterodimer, homotrimer, heterotrimer, homomultimer, heteromultimer).
- a multimerization domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.
- multimerization domains suitable for use in particular embodiments contemplated herein include an FK506 binding protein (FKBP) polypeptide or variants thereof, an FKBP-rapamycin binding (FRB) polypeptide or variants thereof, a calcineurin polypeptide or variants thereof, a cyclophilin polypeptide or variants thereof, a bacterial dihydrofolate reductase (DHFR) polypeptide or variants thereof, a PYRl-like 1 (PYL1) polypeptide or variants thereof, an abscisic acid insensitive 1 (ABI1) polypeptide or variants thereof, a GIB 1 polypeptide or variants thereof, or a GAI polypeptide or variants thereof.
- FKBP FK506 binding protein
- a calcineurin polypeptide or variants thereof a cyclophilin polypeptide or variants thereof
- DHFR bacterial dihydrofolate reductase
- FKBP-rapamycin binding polypeptide refers to an FRB polypeptide.
- the FRB polypeptide is an FKBP 12-rapamy cin binding polypeptide.
- FRB polypeptides suitable for use in particular embodiments contemplated herein generally contain at least about 85 to about 100 amino acid residues.
- the FRB polypeptide comprises a 93 amino acid sequence Ile-2021 through Lys -2113 and a mutation of T2098L, with reference to GenBank Accession No. L34075.1.
- An FRB polypeptide contemplated herein binds to an FKBP polypeptide through a bridging factor, thereby forming a ternary complex.
- FK506 binding protein refers to an FKBP polypeptide.
- the FKBP polypeptide is an FKBP12 polypeptide or an FKBP12 polypeptide comprising an F36V mutation.
- an FKBP domain may also be referred to as a “rapamycin binding domain”.
- Information concerning the nucleotide sequences, cloning, and other aspects of various FKBP species is known in the art (see, e.g., Staendart etal., Nature 346: 671, 1990 (human FKBP12); Kay, Biochem. ./. 314:361, 1996).
- An FKBP polypeptide contemplated herein binds to an FRB polypeptide through a bridging factor, thereby forming a ternary complex.
- a “bridging factor” refers to a molecule that associates with and that is disposed between two or more multimerization domains.
- multimerization domains substantially contribute to or efficiently promote formation of a polypeptide complex only in the presence of a bridging factor.
- multimerization domains do not contribute to or do not efficiently promote formation of a polypeptide complex in the absence of a bridging factor.
- bridging factors suitable for use in particular embodiments contemplated herein include, but are not limited to AP21967, rapamycin (sirolimus) or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FKCsA or a derivative thereof, trimethoprim (Tmp)-synthetic ligand for FKBP (SLF) or a derivative thereof, or any combination thereof.
- AP21967 rapamycin (sirolimus) or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FKCsA or a derivative thereof, trimethoprim (
- Rapamycin analogs include, but are not limited to, those disclosed in U.S. Pat. No. 6,649,595, which rapalog structures are incorporated herein by reference in their entirety.
- a bridging factor is a rapalog with substantially reduced immunosuppressive effect as compared to rapamycin.
- rapalogs suitable for use in particular embodiments contemplated herein include, but are not limited to, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- a “substantially reduced immunosuppressive effect” refers to at least less than 0.1 to 0.005 times the immunosuppressive effect observed or expected for the same dose measured either clinically or in an appropriate in vitro (e.g., inhibition of T cell proliferation) or in vivo surrogate of human immunosuppressive activity.
- a “transmembrane domain” or “TM domain” is a domain that anchors a polypeptide to the plasma membrane of a cell.
- the TM domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.
- effector function refers to a specialized function of an immune effector cell. Effector function includes, but is not limited to, activation, cytokine production, proliferation and cytotoxic activity, including the release of cytotoxic factors, or other cellular responses elicited with antigen binding to the receptor expressed on the immune effector cell.
- intracellular signaling domain refers to the portion of a protein which transduces the effector function signal and that directs the cell to perform a specialized function. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire domain. To the extent that a truncated portion of an intracellular signaling domain is used, such truncated portion may be used in place of the entire domain as long as it transduces an effector function signal.
- intracellular signaling domain is meant to include any truncated portion of an intracellular signaling domain necessary or sufficient to transduce an effector function signal.
- T cell activation can be said to be mediated by two distinct classes of intracellular signaling domains: primary signaling domains that initiate antigen-dependent primary activation through the TCR (e.g, a TCR/CD3 complex) and costimulatory signaling domains that act in an antigen-independent manner to provide a secondary or costimulatory signal.
- primary signaling domains that initiate antigen-dependent primary activation through the TCR
- costimulatory signaling domains that act in an antigen-independent manner to provide a secondary or costimulatory signal.
- costimulatory signaling domain refers to an intracellular signaling domain of a costimulatory molecule.
- Costimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors that provide a second signal required for efficient activation and function of T lymphocytes upon binding to antigen.
- Illustrative examples of such costimulatory molecules from which costimulatory domains may be isolated include, but are not limited to: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARDl 1), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DNAX- Activation Protein 10 (DAP 10), FYN, Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), LCK, T cell receptor associated transmembrane adaptor 1 (TRA
- cancer relates generally to a class of diseases or conditions in which abnormal cells divide without control and can invade nearby tissues.
- malignant refers to a cancer in which a group of tumor cells display one or more of uncontrolled growth (i.e ., division beyond normal limits), invasion ⁇ i.e., intrusion on and destruction of adjacent tissues), and metastasis ⁇ i.e., spread to other locations in the body via lymph or blood).
- metastasize refers to the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor.
- Benign or “non-malignant” refers to tumors that may grow larger but do not spread to other parts of the body. Benign tumors are self-limited and typically do not invade or metastasize.
- a “cancer cell” refers to an individual cell of a cancerous growth or tissue. Cancer cells include both solid cancers and liquid cancers.
- a “tumor” or “tumor cell” refers generally to a swelling or lesion formed by an abnormal growth of cells, which may be benign, pre-malignant, or malignant. Most cancers form tumors, but liquid cancers, e.g., leukemia, do not necessarily form tumors. For those cancers that form tumors, the terms cancer (cell) and tumor (cell) are used interchangeably.
- the amount of a tumor in an individual is the “tumor burden” which can be measured as the number, volume, or weight of the tumor.
- relapse refers to the diagnosis of return, or signs and symptoms of return, of a cancer after a period of improvement or remission.
- Remission is also referred to as “clinical remission,” and includes both partial and complete remission. In partial remission, some, but not all, signs and symptoms of cancer have disappeared. In complete remission, all signs and symptoms of cancer have disappeared, although cancer still may be in the body.
- Refractory refers to a cancer that is resistant to, or non-responsive to, therapy with a particular therapeutic agent.
- a cancer can be refractory from the onset of treatment (i.e., non-responsive to initial exposure to the therapeutic agent), or as a result of developing resistance to the therapeutic agent, either over the course of a first treatment period or during a subsequent treatment period.
- Antigen negative refers to a cell that does not express antigen or expresses a neglible amount of antigen that is undetectable. In one embodiment, antigen negative cells do not bind receptors directed to the antigen. In one embodiment, antigen negative cells do not substantially bind receptors directed to the antigen.
- the terms “individual” and “subject” are often used interchangeably and refer to any animal that exhibits a symptom of cancer or other immune disorder that can be treated with the compositions and methods contemplated elsewhere herein.
- Suitable subjects e.g, patients
- laboratory animals such as mouse, rat, rabbit, or guinea pig
- farm animals such as a cat or dog
- domestic animals or pets such as a cat or dog
- Non-human primates and, preferably, human patients are included.
- Typical subjects include human patients that have, have been diagnosed with, or are at risk or having, cancer or another immune disorder.
- the term “patient” refers to a subject that has been diagnosed with cancer or another immune disorder that can be treated with the compositions and methods disclosed elsewhere herein.
- treatment includes any beneficial or desirable effect on the symptoms or pathology of a disease or pathological condition, and may include even minimal reductions in one or more measurable markers of the disease or condition being treated. Treatment can involve optionally either the reduction of the disease or condition, or the delaying of the progression of the disease or condition, e.g., delaying tumor outgrowth. “Treatment” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.
- prevention indicates an approach for preventing, inhibiting, or reducing the likelihood of the occurrence or recurrence of, a disease or condition. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease or condition. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and/or burden of a disease or condition prior to onset or recurrence of the disease or condition.
- the phrase “ameliorating at least one symptom of’ refers to decreasing one or more symptoms of the disease or condition for which the subject is being treated.
- the disease or condition being treated is a cancer, wherein the one or more symptoms ameliorated include, but are not limited to, weakness, fatigue, shortness of breath, easy bruising and bleeding, frequent infections, enlarged lymph nodes, distended or painful abdomen (due to enlarged abdominal organs), bone or joint pain, fractures, unplanned weight loss, poor appetite, night sweats, persistent mild fever, and decreased urination (due to impaired kidney function).
- “enhance” or “promote,” or “increase” or “expand” refers generally to the ability of a composition contemplated herein to produce, elicit, or cause a greater physiological response (i.e., downstream effects) compared to the response caused by either vehicle or a control molecule/composition.
- a measurable physiological response may include an increase in T cell expansion, activation, persistence, cytokine secretion, and/or an increase in cancer cell killing ability, among others apparent from the understanding in the art and the description herein.
- An “increased” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (e.g ., 500, 1000 times) (including all integers and decimal points in between and above 1, e.g., 1.5, 1.6, 1.7. 1.8, etc.) the response produced by vehicle or a control composition.
- composition contemplated herein refers generally to the ability of composition contemplated herein to produce, elicit, or cause a lesser physiological response (i.e., downstream effects) compared to the response caused by either vehicle or a control molecule/composition.
- a “decrease” or “reduced” amount is typically a “statistically significant” amount, and may include a decrease that is 1.1, 1.2,
- ком ⁇ онент or “preserve,” or “maintenance,” or “no change,” or “no substantial change,” or “no substantial decrease” refers generally to the ability of a composition contemplated herein to produce, elicit, or cause a substantially similar or comparable physiological response (i.e., downstream effects) in a cell, as compared to the response caused by either vehicle, a control molecule/composition, or the response in a particular cell lineage.
- a comparable response is one that is not significantly different or measurable different from the reference response.
- one or more DARJC receptors that redirect cytotoxicity of immune effector cells toward cancer cells expressing a target antigen and that recruit and activate a TCR complex are contemplated.
- the term “DARIC receptor” refers to one or more non-naturally occurring polypeptides that facilitates transduction of an immunostimulatory signal in an immune effector cell upon exposure to target antigen and a multimerizing agent or bridging factor, e.g, stimulating immune effector cell activity and function through activation of a TCR complex.
- a DARIC is a multi-chain chimeric receptor comprising a DARIC signaling component that binds a target antigen and a DARIC binding component that binds a member of a TCR complex.
- a DARIC signaling component and a DARIC binding component are expressed from the same cell. In another embodiment, a DARIC signaling component and a DARIC binding component are expressed from different cells. In a particular embodiment, a DARIC signaling component is expressed from a cell and a DARIC binding component is supplied exogenously, as a polypeptide. In one embodiment, a DARIC binding component pre-loaded with a bridging factor is supplied exogenously to a cell expressing a DARIC signaling component.
- a “DARIC signaling component” or “DARIC signaling polypeptide” refers to a polypeptide comprising a binding domain that binds a target antigen, one or more multimerization domains, a transmembrane domain, and one or more intracellular signaling domains.
- a DARIC signaling component comprises a binding domain that binds a target antigen, a multimerization domain, a transmembrane domain, a costimulatory domain and/or a primary signaling domain.
- a DARIC signaling component comprises a binding domain that binds a target antigen, a first multimerization domain, a first transmembrane domain, a first costimulatory domain and/or a primary signaling domain.
- a DARIC signaling component comprises a binding domain that binds a target antigen.
- the target antigen is an antigen expressed on a target cell, including, for example, cancer cells.
- a DARIC signaling component comprises a binding domain that comprises an antibody or antigen binding fragment thereof directed against one or more target antigens.
- Antigen binding fragments directed against one or more target antigens suitable for use in particular embodiments contemplated herein include those selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- the binding domain comprises an scFv.
- the binding domain comprises a VHH antibody.
- the DARIC signaling components contemplated in particular embodiments comprise a binding domain that binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb6 integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD 123, CD 133, CD 138, CD171, carcinoembryonic antigen (CEA), C-type lectin-like molecule- 1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epit
- the binding domain binds a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- a target antigen selected from the group consisting of: BCMA, B7-H3 (CD276), CD19, CD20, CD22, CD33, CD79a, CD79b, CD 123, CLL-1, EGFR, EGFRvIII, MUC16, and PRAME.
- a DARIC signaling component comprises one or more multimerization domains.
- multimerization domains suitable for use in particular DARIC signaling components contemplated herein include, but are not limited to, an FK506 binding protein (FKBP) polypeptide or variants thereof, an FKBP-rapamycin binding (FRB) polypeptide or variants thereof, a calcineurin polypeptide or variants thereof, a cyclophilin polypeptide or variants thereof, a bacterial dihydrofolate reductase (DHFR) polypeptide or variants thereof, a PYRl-like 1 (PYL1) polypeptide or variants thereof and an abscisic acid insensitive 1 (ABIl) polypeptide or variants thereof.
- FKBP FK506 binding protein
- a calcineurin polypeptide or variants thereof a cyclophilin polypeptide or variants thereof
- DHFR bacterial dihydrofolate reductase
- PYL1 PYRl-like 1
- ABSIl
- a DARIC signaling component comprises an FRB polypeptide.
- a DARIC signaling component comprises an FRB polypeptide comprising a T2098L mutation, or variant thereof.
- a DARIC signaling component comprises an FRB polypeptide comprising a T2098L mutation, or variant thereof.
- a DARIC signaling component comprises an FKBP 12 polypeptide or variant thereof.
- a DARIC signaling component comprises an FKBP12 polypeptide comprising aF36V mutation.
- a DARIC signaling component comprises a transmembrane domain.
- transmembrane domains suitable for use in particular DARIC signaling components contemplated herein include, but are not limited to, the transmembrane region(s) of the alpha, beta, gamma, or delta chain of a T-cell receptor, CD3e, CD3C, CD4, CD5, CD8a, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD71, CD80, CD86, CD 134, CD137, CD152, CD 154, amnionless (AMN), and programmed cell death 1 (PDCD1).
- a DARIC signaling component comprises a CD8a transmembrane domain or a CD4 transmembrane domain.
- a DARIC signaling component comprises a CD4 transmembrane domain.
- a DARIC signaling component comprises a linker that links one or more domains therein.
- a linker polypeptide is disposed between the C-terminus of the binding domain and the N-terminus of the transmembrane domain.
- a short oligo- or poly-peptide linker is about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length.
- a glycine-serine based linker provides a particularly suitable linker.
- a linker polypeptide is disposed between the C-terminus of the transmembrane domain and the N-terminus of an intracellular signaling domain.
- a short oligo- or poly-peptide linker preferably between 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length links the transmembrane domain and an intracellular signaling domain.
- a glycine-serine based linker provides a particularly suitable linker.
- DARIC signaling components contemplated in particular embodiments herein comprise one or more intracellular signaling domains.
- a DARIC signaling component comprises one or more costimulatory signaling domains and/or a primary signaling domain.
- the intracellular signaling domain comprises an immunoreceptor tyrosine activation motif (IT AM).
- IT AM containing primary signaling domains that are suitable for use in particular DARIC signaling components contemplated herein include, but are not limited to those derived from FcRy, FcRP, CD3y, CD35, CD3e, CD3 ⁇ CD22, CD79a, CD79b, and CD66d.
- a DARIC signaling component comprises one or more costimulatory signaling domains and optionally a CD3z primary signaling domain.
- the primary signaling and costimulatory signaling domains may be linked in any order in tandem to the carboxyl terminus of the transmembrane domain.
- costimulatory domains suitable for use in particular DARIC signaling components contemplated herein include, but are not limited to those domains isolated from the following costimulatory molecules: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DN AX- Activation Protein 10 (DAP10), FYN, Linker for activation of T-cells family member 1 (LAT), LCK, SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRATl), TNFR2, TNFRS14, TNFRS18, TNRFS25, and zeta chain of TLR1 (C
- a DARIC signaling component contemplated herein comprises a signal peptide, e.g., secretion signal peptide, and do not comprise a transmembrane domain.
- signal peptides suitable for use in particular DARIC signaling components include but are not limited to an IgGl heavy chain signal polypeptide, an IgK light chain signal polypeptide, a CD8a signal polypeptide, or a human GM-CSF receptor alpha signal polypeptide.
- a DARIC signaling component comprises an IgK light chain signal polypeptide.
- a DARIC signaling component comprises one or more costimulatory signaling domains selected from the group consisting of CD28, CD137,
- a DARIC signaling component comprises one or more costimulatory signaling domains selected from the group consisting of FYN, LCK, and ZAP70.
- a DARIC signaling component comprises one or more costimulatory signaling domains selected from the group consisting of FYN, LCK, and ZAP70, and a CD3z primary signaling domain.
- a DARIC signaling component comprises a binding domain comprising a VHH or scFv that binds a target antigen, an FKBP12 multimerization domain, a CD4 transmembrane domain, optionally, a LCK costimulatory domain and optionally, a O ⁇ 3z primary signaling domain.
- a “DARIC binding component” or “DARIC binding polypeptide” refers to a polypeptide comprising a binding domain that binds CD3e, CD35, or CD3y, one or more multimerization domains a transmembrane domain, and optionally a costimulatory domain.
- a “DARIC binding component” or “DARIC binding polypeptide” refers to a polypeptide comprising a multimerization domain polypeptide or variant thereof, a linker polypeptide, and a CD3e, CD35, or CD3y polypeptide; and optionally a costimulatory domain.
- binding domains suitable for use in particular DARIC binding components include, but are not limited to, antibodies or antigen binding fragments thereof, that bind to one or more epitopes of a CD3e, CD35, or CD3y polypeptide, including, for example, the OKT3 antibody, which binds CD3e.
- CD3 antibodies include, but are not limited to, G19-4, BC3, and 64.1.
- Illustrative examples of antibodies and antigen binding fragments thereof suitable for use in particular DARIC binding components include, but are not limited to, a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')2 fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (SCFV)2, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody).
- a Camel Ig a Llama Ig, an Alpaca Ig, Ig NAR
- Fab' fragment fragment
- F(ab')2 fragment fragment
- Fab2 bispecific Fab
- antibodies and antigen binding fragments thereof suitable for use in particular DARIC binding components include, but are not limited to, murine antibodies, camelid antibodies, chimeric antibodies, humanized antibodies, or human antibodies.
- the antibody or antigen binding fragment thereof is derived from a monoclonal antibody.
- the binding domain comprises one or more humanized camelid VHH antibodies that bind to one or more epitopes of a CD3e, CD35, or CD3y polypeptide.
- the binding domain is a humanized or human scFv that binds to one or more epitopes of a CD3e, CD35, or CD3y polypeptide.
- a DARIC binding component comprises one or more multimerization domains.
- multimerization domains suitable for use in particular DARIC binding components contemplated herein include, but are not limited to, an FKBP polypeptide or variants thereof, an FRB polypeptide or variants thereof, a calcineurin polypeptide or variants thereof, a cyclophilin polypeptide or variants thereof, a DHFR polypeptide or variants thereof, a PYL1 polypeptide or variants thereof and an ABI1 polypeptide or variants thereof.
- a DARIC binding component comprises an FRB polypeptide or variant thereof and a DARIC signaling component comprises an FKBP polypeptide or variant thereof.
- a DARIC binding component comprises an FRB polypeptide comprising a T2098L mutation, or variant thereof and a DARIC signaling component comprises an FKBP12 polypeptide or variant thereof.
- a DARIC binding component comprises an FKBP polypeptide or variant thereof and a DARIC signaling component comprises an FRB polypeptide, or variant thereof.
- a DARIC binding component comprises an FKBP12 polypeptide, or variant thereof and a DARIC signaling component comprises an FRB polypeptide comprising a T2098L mutation, or variant thereof.
- a DARIC binding component comprises a transmembrane domain.
- the transmembrane domain may be the same as the transmembrane domain used in the DARIC signaling component. In one embodiment, the transmembrane domain may be different from the transmembrane domain used in the DARIC signaling component.
- transmembrane domains suitable for use in particular DARIC binding components contemplated herein include, but are not limited to, the transmembrane region(s) of the alpha, beta, gamma, or delta chain of a T-cell receptor, CD3e, CD3C, CD4, CD5, CD8a, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD71, CD80, CD86, CD 134, CD137, CD152, CD 154, amnionless (AMN), and programmed cell death 1 (PDCD1).
- a DARIC binding component comprises a CD8a transmembrane domain or a CD4 transmembrane domain.
- a DARIC binding component comprises a CD8a transmembrane domain.
- a short oligo- or poly-peptide linker preferably between 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length links one or more domains in the DARIC binding component.
- a glycine-serine based linker provides a particularly suitable linker.
- DARIC binding components contemplated in particular embodiments herein do not comprise one or more intracellular signaling domains.
- DARIC binding components contemplated herein comprise one or more intracellular signaling domains.
- the DARIC binding component comprises one or more intracellular signaling domains, those domains are different that the intracellular signaling domains present in the cognate DARIC signaling component.
- a DARIC binding component comprises a costimulatory signaling domain.
- costimulatory domains suitable for use in particular DARIC signaling components contemplated herein include, but are not limited to those domains isolated from the following costimulatory molecules: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (0X40), CD137 (4-1BB), CD278 (ICOS), DN AX- Activation Protein 10 (DAP10), Linker for activation of T-cells family member 1 (LAT), SH2 Domain- Containing Leukocyte Protein Of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2, TNF receptor superfamily member 14 (TNFRS14; HVEM), TNF receptor superfamily member 18 (TNFRS18
- a DARIC binding component contemplated herein comprises a signal peptide, e.g., secretion signal peptide, and do not comprise a transmembrane domain.
- signal peptides suitable for use in particular DARIC binding components include but are not limited to an IgGl heavy chain signal polypeptide, an IgK light chain signal polypeptide, a CD8a signal polypeptide, or a human GM-CSF receptor alpha signal polypeptide.
- a DARIC binding component comprises a CD8a signal polypeptide.
- a DARIC binding component comprises an scFv or VHH that binds to CD3e, CD35, or CD3y, an FRB T2098L multimerization domain, and a CD8a transmembrane domain and optionally, a costimulatory domain.
- a DARIC binding component comprises an scFv or VHH that binds to CD3e, an FRB T2098L multimerization domain, and a CD8a transmembrane domain and optionally, a costimulatory domain.
- a DARIC binding component comprises an scFv or VHH that binds to CD35, an FRB T2098L multimerization domain, and a CD8a transmembrane domain and optionally, a costimulatory domain.
- a DARIC binding component comprises an scFv or VHH that binds to CD3y, an FRB T2098L multimerization domain, and a CD8a transmembrane domain and optionally, a costimulatory domain.
- a DARIC binding component comprises an FRB T2098L multimerization domain, a linker polypeptide, and a CD3e, CD35, or CD3y polypeptide.
- a DARIC binding component comprises an FRB T2098L multimerization domain, a linker polypeptide, and a CD3e polypeptide.
- a DARIC binding component comprises an FRB T2098L multimerization domain, a linker polypeptide, and a CD35 polypeptide.
- a DARIC binding component comprises an FRB T2098L multimerization domain, a linker polypeptide, and a CD3y polypeptide.
- Bridging factors contemplated in particular embodiments herein mediate or promote the association of one or more DARIC signaling components with one or more DARIC binding components through multimerization domains in the respective components.
- a bridging factor associates with and is disposed between the multimerization domains to promote association of a DARIC signaling component and a DARIC binding component.
- the DARIC binding component and the DARIC signaling component associate with a TCR receptor complex and initiate immune effector cell activity against a target cell when the DARIC binding polypeptide is bound to a target antigen on the target cell.
- the DARIC binding component does not associate with the DARIC signaling component, does not recruit a TCR complex and the DARIC is inactive.
- a DARIC signaling component and a DARIC binding component comprise a cognate pair of multimerization domains selected from the group consisting of: FKBP and FKBP12-rapamycin binding (FRB), FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYRldike 1 (PYL1) and abscisic acid insensitive 1 (ABI1).
- FKBP and FKBP12-rapamycin binding FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYRldike 1 (PYL1) and abscisic acid insensitive 1 (ABI1).
- the multimerization domains of DARIC signaling and binding components associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A (FKCsA) or a derivative thereof, and trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof.
- a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK50
- a DARIC signaling component and a DARIC binding component comprise one or more FRB and/or FKBP multimerization domains or variants thereof.
- a DARIC signaling component comprises an FKBP12 multimerization domain or variant thereof and a DARIC binding component comprises an FRB multimerization domain or variant thereof.
- a DARIC signaling component comprises an FKBP 12 or FKBP 12 F36V multimerization domain or variant thereof and a DARIC binding component comprises an FRB T2098L multimerization domains or variant thereof.
- bridging factors suitable for use in particular embodiments contemplated herein include, but are not limited to, AP1903, AP20187, AP21967 (also known as C-16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
- the bridging factor is AP21967.
- the bridging factor is a non-immunosuppressive dose of sirolimus (rapamycin).
- a cell is engineered or modified to express a DARIC that binds a target antigen and recruits a TCR complex and an engineered antigen receptor.
- a nucleic acid or vector encodes a fusion polypeptide comprising an engineered receptor and a DARIC binding component and/or a DARIC signaling component, and one or more polypeptide cleavage signals interspersed between the receptor and the components.
- a polynucleotide or vector encoding a DARIC is introduced into an immune effector cell that comprises an engineered antigen receptor.
- any mechanism known in the art may be used to introduce and co-express an engineered antigen receptor and a DARIC in the same immune effector cell or population of cells to the efficiency, potency, and durability of the immune effector cell response.
- the intracellular signaling domains, e.g., costimulatory domains, of the engineered antigen receptor and the DARIC signaling domains and/or the DARIC binding will be different from each other.
- immune effector cells contemplated herein comprise an engineered antigen receptor and one or more components of a DARIC.
- the engineered antigen receptor is an engineered T cell receptor (TCR), a chimeric antigen receptor (CAR), or a zetakine.
- immune effector cells contemplated herein comprise an engineered TCR and a DARIC.
- immune effector cells contemplated herein comprise an engineered TCR that is recruited by a DARIC receptor.
- the DARIC binding components contemplated in particular embodiments comprise a binding domain that binds CD3e, CD35 or CD3y and thus, in the presence of bridging factor, a DARIC receptor recruits a TCR complex by binding CD3e, CD35 or CD3y.
- the DARIC binding components contemplated in particular embodiments comprise a multimerization domain fused to CD3e, CD35 or CD3y through a linker polypeptide and thus, in the presence of bridging factor, a DARIC signaling component recruits a TCR complex by binding to the CD3e, CD35 or CD3y polypeptide comprising a multimerization domain.
- T cells are engineered by introducing a polynucleotide or vector encoding an engineered TCR and one or more components of a DARIC separated by one or more polypeptide cleavage signals. In one embodiment, T cells are engineered by introducing a polynucleotide or vector encoding an engineered TCR and a polynucleotide or vector encoding one or more components of a DARIC. In one embodiment, T cells are engineered to express an engineered TCR are further engineered by introducing a polynucleotide or vector encoding one or more components of a DARIC.
- Naturally occurring T cell receptors comprise two subunits, an alpha chain and a beta chain subunit (a.pTCR), or a gamma chain and a delta chain subunit (ydTCR), each of which is a unique protein produced by recombination event in each T cell’s genome.
- Libraries of TCRs may be screened for their selectivity to particular target antigens. In this manner, natural TCRs, which have a high-avidity and reactivity toward target antigens may be selected, cloned, and subsequently introduced into a population of T cells used for adoptive immunotherapy.
- the TCR is an abTOI.
- the TCR is a ydTCR.
- T cells are modified by introducing a TCR subunit that has the ability to form TCRs that confer specificity to T cells for tumor cells expressing a target antigen.
- the subunits have one or more amino acid substitutions, deletions, insertions, or modifications compared to the naturally occurring subunit, so long as the subunits retain the ability to form TCRs and confer upon transfected T cells the ability to home to target cells, and participate in immunologically-relevant cytokine signaling.
- the engineered TCRs preferably also bind target cells displaying the relevant tumor-associated peptide with high avidity, and optionally mediate efficient killing of target cells presenting the relevant peptide in vivo.
- the nucleic acids encoding engineered TCRs are preferably isolated from their natural context in a (naturally-occurring) chromosome of a T cell, and can be incorporated into suitable vectors as described elsewhere herein. Both the nucleic acids and the vectors comprising them can be transferred into a cell, preferably a T cell in particular embodiments. The modified T cells are then able to express one or more chains of a TCR encoded by the transduced nucleic acid or nucleic acids.
- the engineered TCR is an exogenous TCR because it is introduced into T cells that do not normally express the particular TCR.
- the essential aspect of the engineered TCRs is that it has high avidity for a tumor antigen presented by a major histocompatibility complex (MHC) or similar immunological component.
- MHC major histocompatibility complex
- CARs are engineered to bind target antigens in an MHC independent manner.
- the TCR can be expressed with additional polypeptides attached to the amino- terminal or carboxyl -terminal portion of the alpha chain or beta chain of a TCR, or of the gamma chain or delta chain of a TCR so long as the attached additional polypeptide does not interfere with the ability of the alpha chain or beta chain to form a functional T cell receptor and the MHC dependent antigen recognition.
- Antigens that are recognized by the engineered TCRs contemplated in particular embodiments include, but are not limited to cancer antigens, including antigens on both hematological cancers and solid tumors.
- Illustrative antigens include, but are not limited to alpha folate receptor (FRa), a n b6 integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD 16, CD 19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD 123, CD 133, CD 138, CD171, carcinoembryonic antigen (CEA), C-type lectin-like molecule- 1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated anti
- immune effector cells contemplated herein comprise a CAR and a DARIC.
- Chimeric antigen receptors are molecules that combine antibody -based specificity for a target antigen (e.g ., tumor antigen) with a T cell receptor activating intracellular domain to generate a chimeric protein that exhibits a specific anti tumor cellular immune activity.
- target antigen e.g ., tumor antigen
- T cell receptor activating intracellular domain e.g., tumor antigen
- chimeric describes being composed of parts of different proteins or DNAs from different origins.
- immune effector cells contemplated herein comprise one or more chains of a zetakine receptor and a DARIC.
- Zetakines are chimeric transmembrane immunoreceptors that comprise an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signaling domain.
- Zetakines when expressed on the surface of T lymphocytes, direct T cell activity to those cells expressing a receptor for which the soluble receptor ligand is specific.
- Zetakine chimeric immunoreceptors redirect the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrine/paracrine cytokine systems utilized by human malignancy.
- polypeptides are contemplated herein, including, but not limited to,
- a polypeptide comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-5.
- Polypeptide “peptide” and “protein” are used interchangeably, unless specified to the contrary, and according to conventional meaning, i.e., as a sequence of amino acids.
- a “polypeptide” includes fusion polypeptides and other variants. Polypeptides can be prepared using any of a variety of well-known recombinant and/or synthetic techniques.
- Polypeptides are not limited to a specific length, e.g., they may comprise a full-length protein sequence, a fragment of a full- length protein, or a fusion protein, and may include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
- fusion polypeptides, polypeptides, fragments and other variants thereof are prepared, obtained, or isolated from one or more human polypeptides.
- an isolated polypeptide is a synthetic polypeptide, a semi -synthetic polypeptide, or a polypeptide obtained or derived from a recombinant source.
- Polypeptides include “polypeptide variants.” Polypeptide variants may differ from a naturally occurring polypeptide in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the above polypeptide sequences. For example, in particular embodiments, it may be desirable to improve the binding affinity and/or other biological properties of a polypeptide by introducing one or more substitutions, deletions, additions and/or insertions the polypeptide.
- polypeptides include polypeptides having at least about 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,
- the biological activity is binding affinity.
- the biological activity is enzymatic activity.
- a DARIC that recruits a TCR complex comprises a polypeptide complex comprising (i) a first polypeptide, e.g., first fusion polypeptide, having a first multimerization domain and (ii) second polypeptide, e.g, second fusion polypeptide, having a second multimerization domain.
- the multimerization domains are the same; in certain embodiments, the first multimerization domain is different than the second multimerization domain.
- the first and second multimerization domains substantially contribute to or efficiently promote formation of the polypeptide complex in the presence of a bridging factor.
- the interaction(s) between the first and second multimerization domains substantially contributes to or efficiently promotes the multimerization of the first and second fusion polypeptides if there is a statistically significant reduction in the association between the first and second fusion polypeptides in the absence of the first multimerization domain, the second multimerization domain, or the bridging factor.
- the first and second fusion polypeptides when the first and second fusion polypeptides are co-expressed, at least about 60%, for instance, at least about 60% to about 70%, at least about 70% to about 80%, at least about 80% to about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, and at least about 90% to about 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the first and second single chain polypeptides form multimers with each other in the presence of a bridging factor.
- Polypeptides variants include biologically active “polypeptide fragments.”
- biologically active polypeptide fragments include binding domains, intracellular signaling domains, and the like.
- biologically active fragment or minimal biologically active fragment refers to a polypeptide fragment that retains at least 100%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or at least 5% of the naturally occurring polypeptide activity.
- a polypeptide fragment can comprise an amino acid chain at least 5 to about 1700 amino acids long. It will be appreciated that in certain embodiments, fragments are at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
- polypeptides set forth herein may comprise one or more amino acids denoted as “X.” “X’ if present in an amino acid SEQ ID NO, refers to any one or more amino acids.
- SEQ ID NOs denoting a fusion protein comprise a sequence of continuous X residues that cumulatively represent any amino acid sequence.
- polypeptides may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art.
- amino acid sequence variants of a reference polypeptide can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985, Proc. Natl. Acad. Sci. USA. 82: 488-492), Kunkel eta , (1987, Methods in Fnzymo!, 154: 367- 382), U.S. Pat. No. 4,873,192, Watson, J. D. el al. , ( Molecular Biology of the Gene , Fourth
- a polypeptide variant comprises one or more conservative substitutions.
- a “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged.
- Modifications may be made in the structure of the polynucleotides and polypeptides contemplated in particular embodiments and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics.
- a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics.
- one skilled in the art for example, can change one or more of the codons of the encoding DNA sequence, e.g, according to Table 1.
- amino acid changes in the protein variants disclosed herein are conservative amino acid changes, i.e., substitutions of similarly charged or uncharged amino acids.
- a conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains.
- Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and generally can be made without altering a biological activity of a resulting molecule.
- polypeptide sequences encoding them can be separated by an IRES sequence as disclosed elsewhere herein.
- Polypeptides contemplated in particular embodiments include fusion polypeptides.
- fusion polypeptides and polynucleotides encoding fusion polypeptides are provided.
- Fusion polypeptides and fusion proteins refer to a polypeptide having at least two, three, four, five, six, seven, eight, nine, or ten polypeptide segments.
- a fusion polypeptide comprises one or more DARIC components.
- the fusion polypeptide comprises a DARIC binding component and a DARIC signaling component.
- two or more DARIC components and/or other polypeptides can be expressed as a fusion protein that comprises one or more self-cleaving peptide sequences between the polypeptides as disclosed elsewhere herein.
- a fusion polypeptide comprises a DARIC binding component and one or more DARIC signaling components.
- Fusion polypeptides can comprise one or more polypeptide domains or segments including, but are not limited to signal peptides, cell permeable peptide domains (CPP), binding domains, signaling domains, etc ., epitope tags (e.g, maltose binding protein (“MBP”), glutathione S transferase (GST), HIS6, MYC, FLAG, V5, VSV-G, and HA), polypeptide linkers, and polypeptide cleavage signals.
- Fusion polypeptides are typically linked C-terminus to N-terminus, although they can also be linked C-terminus to C-terminus, N-terminus to N- terminus, or N-terminus to C-terminus.
- the polypeptides of the fusion protein can be in any order. Fusion polypeptides or fusion proteins can also include conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, and interspecies homologs, so long as the desired activity of the fusion polypeptide is preserved. Fusion polypeptides may be produced by chemical synthetic methods or by chemical linkage between the two moieties or may generally be prepared using other standard techniques. Ligated DNA sequences comprising the fusion polypeptide are operably linked to suitable transcriptional or translational control elements as disclosed elsewhere herein.
- Fusion polypeptides may optionally comprise one or more linkers that can be used to link the one or more polypeptides or domains within a polypeptide.
- a peptide linker sequence may be employed to separate any two or more polypeptide components by a distance sufficient to ensure that each polypeptide folds into its appropriate secondary and tertiary structures so as to allow the polypeptide domains to exert their desired functions.
- Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques in the art.
- Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes.
- preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence.
- Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al, Gene 40:39-46, 1985; Murphy el al. , Proc. Natl. Acad. Sci.
- Linker sequences are not required when a particular fusion polypeptide segment contains non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.
- preferred linkers are typically flexible amino acid subsequences which are synthesized as part of a recombinant fusion protein.
- Linker polypeptides can be between 1 and 200 amino acids in length, between 1 and 100 amino acids in length, or between 1 and 50 amino acids in length, including all integer values in between.
- Exemplary polypeptide cleavage signals include polypeptide cleavage recognition sites such as protease cleavage sites, nuclease cleavage sites (e.g., rare restriction enzyme recognition sites, self-cleaving ribozyme recognition sites), and self-cleaving viral oligopeptides ( see deFelipe and Ryan, 2004. Traffic , 5(8); 616-26).
- polypeptide cleavage recognition sites such as protease cleavage sites, nuclease cleavage sites (e.g., rare restriction enzyme recognition sites, self-cleaving ribozyme recognition sites), and self-cleaving viral oligopeptides ( see deFelipe and Ryan, 2004. Traffic , 5(8); 616-26).
- Suitable protease cleavages sites and self-cleaving peptides are known to the skilled person (see, e.g., in Ryan el al, 1997. J. Gener. Virol. 78, 699-722; Scymczak el al. (2004) Nature Biotech. 5, 589-594).
- Exemplary protease cleavage sites include, but are not limited to the cleavage sites of potyvirus NIa proteases (e.g, tobacco etch virus protease), potyvirus HC proteases, potyvirus PI (P35) proteases, byovirus NIa proteases, byovirus RNA-2-encoded proteases, aphthovirus L proteases, enterovirus 2A proteases, rhinovirus 2A proteases, picoma 3C proteases, comovirus 24K proteases, nepovirus 24K proteases, RTSV (rice tungro spherical virus) 3C-like protease, PYW (parsnip yellow fleck virus) 3C-like protease, heparin, thrombin, factor Xa and enterokinase.
- potyvirus NIa proteases e.g, tobacco etch virus protease
- potyvirus HC proteases e.g,
- TEV tobacco etch virus protease cleavage sites
- EXXYXQ(G/S) SEQ ID NO: 17
- ENLYFQG SEQ ID NO: 18
- ENLYFQS SEQ ID NO: 19
- X represents any amino acid (cleavage by TEV occurs between Q and G or Q and S).
- the polypeptide cleavage signal is a viral self-cleaving peptide or ribosomal skipping sequence.
- ribosomal skipping sequences include, but are not limited to: a 2A or 2A4ike site, sequence or domain (Donnelly etal. , 2001. ./. Gen. Virol. 82:1027-1041).
- the viral 2A peptide is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide.
- the viral 2A peptide is selected from the group consisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thosea asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.
- FMDV foot-and-mouth disease virus
- EAV equine rhinitis A virus
- TaV Thosea asigna virus
- PTV-1 porcine teschovirus-1
- Theilovirus 2A peptide a Theilovirus 2A peptide
- an encephalomyocarditis virus 2A peptide Illustrative examples of 2A sites are provided in Table 2.
- a fusion polypeptide comprises one or more DARIC components or DARICs separated by one or more self-cleaving polypeptides.
- a fusion polypeptide comprises a DARIC binding component comprising a binding domain that binds CD3e, CD35 or CD3y, an FRB T2098L multimerization domain, a CD8a transmembrane domain, and optionally, a costimulatory domain; a viral self-cleaving 2A polypeptide; and a DARIC signaling component comprising an antibody or antigen binding fragment thereof, that binds to a target antigen, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain, and optionally, a costimulatory domain.
- a fusion polypeptide comprises a DARIC binding component comprising an FRB T2098L multimerization domain, a linker polypeptide, and a CD3e, CD35 or CD3y polypeptide; a viral self-cleaving 2 A polypeptide; and a DARIC signaling component comprising an antibody or antigen binding fragment thereof, that binds to a target antigen, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain, and optionally, a costimulatory domain.
- a fusion polypeptide comprises a DARIC binding component comprising a CD8a signal sequence, a binding domain that binds CD3e, CD35 or CD3y, an FRB T2098L multimerization domain, a CD8a transmembrane domain; a viral self cleaving 2A polypeptide; and a DARIC signaling component comprising an Ig kappa light chain signal sequence, an antibody or antigen binding fragment thereof, that binds to a target antigen, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain, and optionally, a costimulatory domain selected from the group consisting of: FYN, LCK, ZAP70, 0X40, and TNFR2.
- a fusion polypeptide comprises a DARIC binding component comprising a CD8a signal sequence, an FRB T2098L multimerization domain, a linker polypeptide, and a CD3e, CD35 or CD3y polypeptide; a viral self-cleaving 2A polypeptide; and a DARIC signaling component comprising an Ig kappa light chain signal sequence, an antibody or antigen binding fragment thereof, that binds to a target antigen, an FKBP12 multimerization domain polypeptide, a CD4 transmembrane domain, and optionally, a costimulatory domain selected from the group consisting of: FYN, LCK, ZAP70, 0X40, and TNFR2.
- polynucleotides encoding a DARIC, one or more DARIC components, engineered TCRs, CARs, zetakines, fusion proteins comprising the foregoing polypeptides and fragments thereof are provided.
- polynucleotide or “nucleic acid” refer to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and DNA/RNA hybrids. Polynucleotides may be single-stranded or double-stranded and either recombinant, synthetic, or isolated.
- Polynucleotides include, but are not limited to: pre messenger RNA (pre-mRNA), messenger RNA (mRNA), RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, genomic RNA (gRNA), plus strand RNA (RNA(+)), minus strand RNA (RNA(-)), tracrRNA, crRNA, single guide RNA (sgRNA), synthetic RNA, synthetic mRNA, genomic DNA (gDNA), PCR amplified DNA, complementary DNA (cDNA), synthetic DNA, or recombinant DNA.
- pre-mRNA pre messenger RNA
- mRNA messenger RNA
- RNA short interfering RNA
- shRNA short hairpin RNA
- miRNA microRNA
- ribozymes genomic RNA (gRNA), plus strand RNA (RNA(+)), minus strand RNA (RNA(-)), tracrRNA, crRNA, single guide RNA (sgRNA), synthetic
- Polynucleotides refer to a polymeric form of nucleotides of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 5000, at least 10000, or at least 15000 or more nucleotides in length, either ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide, as well as all intermediate lengths.
- intermediate lengths in this context, means any length between the quoted values, such as 6, 7, 8, 9, etc., 101, 102, 103, etc 151, 152, 153, etc 201, 202, 203, etc.
- polynucleotides or variants have at least or about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a reference sequence.
- isolated polynucleotide refers to a polynucleotide that has been purified from the sequences which flank it in a naturally-occurring state, e.g., a DNA fragment that has been removed from the sequences that are normally adjacent to the fragment.
- an “isolated polynucleotide” also refers to a complementary DNA (cDNA), a recombinant DNA, or other polynucleotide that does not exist in nature and that has been made by the hand of man.
- an isolated polynucleotide is a synthetic polynucleotide, a semi-synthetic polynucleotide, or a polynucleotide obtained or derived from a recombinant source.
- a polynucleotide comprises an mRNA encoding a polypeptide contemplated herein.
- the mRNA comprises a cap, one or more nucleotides, and a poly(A) tail.
- polynucleotides encoding one or more DARIC components may be codon-optimized.
- codon-optimized refers to substituting codons in a polynucleotide encoding a polypeptide in order to increase the expression, stability and/or activity of the polypeptide.
- Factors that influence codon optimization include, but are not limited to one or more of: (i) variation of codon biases between two or more organisms or genes or synthetically constructed bias tables, (ii) variation in the degree of codon bias within an organism, gene, or set of genes, (iii) systematic variation of codons including context, (iv) variation of codons according to their decoding tRNAs, (v) variation of codons according to GC %, either overall or in one position of the triplet, (vi) variation in degree of similarity to a reference sequence for example a naturally occurring sequence, (vii) variation in the codon frequency cutoff, (viii) structural properties of mRNAs transcribed from the DNA sequence, (ix) prior knowledge about the function of the DNA sequences upon which design of the codon substitution set is to be based, (x) systematic variation of codon sets for each amino acid, and/or (xi) isolated removal of spurious translation initiation sites.
- nucleotide refers to a heterocyclic nitrogenous base in N- glycosidic linkage with a phosphorylated sugar. Nucleotides are understood to include natural bases, and a wide variety of art-recognized modified bases. Such bases are generally located at the 1 ' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. In ribonucleic acid (RNA), the sugar is a ribose, and in deoxyribonucleic acid (DNA) the sugar is a deoxyribose, i.e., a sugar lacking a hydroxyl group that is present in ribose.
- RNA ribonucleic acid
- DNA deoxyribonucleic acid
- polynucleotides include, but are not limited to, polynucleotides encoding polypeptides set forth in SEQ ID NOs: 1-5.
- polynucleotides contemplated herein include, but are not limited to polynucleotides encoding one or more DARIC components, DARIC receptors, engineered antigen receptors, fusion polypeptides, and expression vectors, viral vectors, and transfer plasmids comprising polynucleotides contemplated herein.
- polynucleotide variant and “variant” and the like refer to polynucleotides displaying substantial sequence identity with a reference polynucleotide sequence or polynucleotides that hybridize with a reference sequence under stringent conditions that are defined hereinafter. These terms also encompass polynucleotides that are distinguished from a reference polynucleotide by the addition, deletion, substitution, or modification of at least one nucleotide. Accordingly, the terms “polynucleotide variant” and “variant” include polynucleotides in which one or more nucleotides have been added or deleted, or modified, or replaced with different nucleotides.
- sequence identity or, for example, comprising a “sequence 50% identical to,” as used herein, refer to the extent that sequences are identical on a nucleotide- by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison.
- a “percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g A, T, C, G, I) or the identical amino acid residue (e.g, Ala, Pro, Ser, Thr, Gly, Val, Leu, lie, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gin, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- the identical nucleic acid base e.g A, T, C, G, I
- the identical amino acid residue e.g, Ala, Pro, Ser, Thr, Gly, Val, Leu, lie, Phe, Tyr, Trp, Lys, Arg, His, Asp,
- nucleotides and polypeptides having at least about 50%, 55%, 60%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 86%, 97%, 98%, or 99% sequence identity to any of the reference sequences described herein.
- nucleic acid cassette refers to genetic sequences within the vector which can express an RNA, and subsequently a polypeptide.
- the nucleic acid cassette contains a gene(s)-of-interest, e.g. , a polynucleotide(s)-of-interest.
- the nucleic acid cassette contains one or more expression control sequences, e.g. , a promoter, enhancer, poly(A) sequence, and a gene(s)-of-interest, e.g, a polynucleotide(s)-of-interest.
- Vectors may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleic acid cassettes.
- the nucleic acid cassette is positionally and sequentially oriented within the vector such that the nucleic acid in the cassette can be transcribed into RNA, and when necessary, translated into a protein or a polypeptide, undergo appropriate post-translational modifications required for activity in the transformed cell, and be translocated to the appropriate compartment for biological activity by targeting to appropriate intracellular compartments or secretion into extracellular compartments.
- the cassette has its 3 ' and 5 ' ends adapted for ready insertion into a vector, e.g. , it has restriction endonuclease sites at each end.
- the cassette can be removed and inserted into a plasmid or viral vector as a single unit.
- Polynucleotides include polynucleotide(s)-of-interest.
- polynucleotide-of-interest refers to a polynucleotide encoding a polypeptide or fusion polypeptide or a polynucleotide that serves as a template for the transcription of an inhibitory polynucleotide, as contemplated herein.
- polynucleotides contemplated herein may be combined with other DNA sequences, such as promoters and/or enhancers, untranslated regions (UTRs), signal sequences, Kozak sequences, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, internal ribosomal entry sites (IRES), recombinase recognition sites (e.g ., LoxP, FRT, and Att sites), termination codons, transcriptional termination signals, and polynucleotides encoding self-cleaving polypeptides, epitope tags, as disclosed elsewhere herein or as known in the art, such that their overall length may vary considerably. It is therefore contemplated that a polynucleotide fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.
- Polynucleotides can be prepared, manipulated, expressed and/or delivered using any of a variety of well-established techniques known and available in the art.
- a nucleotide sequence encoding the polypeptide can be inserted into appropriate vector.
- vectors include, but are not limited to plasmid, autonomously replicating sequences, and transposable elements, e.g., Sleeping Beauty, PiggyBac.
- vectors include, without limitation, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or PI -derived artificial chromosome (PAC), bacteriophages such as lambda phage or M13 phage, and animal viruses.
- artificial chromosomes such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or PI -derived artificial chromosome (PAC)
- bacteriophages such as lambda phage or M13 phage
- animal viruses include, without limitation, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or PI -derived artificial chromosome (PAC), bacteriophages such as lambda phage or M13 phage, and animal viruses.
- viruses useful as vectors include, without limitation, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpesvirus (e.g, herpes simplex virus), poxvirus, baculovirus, papillomavirus, and papovavirus (e.g, SV40).
- retrovirus including lentivirus
- adenovirus e.g, adeno-associated virus
- herpesvirus e.g, herpes simplex virus
- poxvirus baculovirus
- papillomavirus papillomavirus
- papovavirus e.g, SV40
- expression vectors include, but are not limited to, pClneo vectors (Promega) for expression in mammalian cells; pLenti4/V5-DESTTM, pLenti6/V5- DESTTM, and pLenti6.2/V5-GW/lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells.
- coding sequences of polypeptides disclosed herein can be ligated into such expression vectors for the expression of the polypeptides in mammalian cells.
- the vector is an episomal vector or a vector that is maintained extrachromosomally.
- episomal vector refers to a vector that is able to replicate without integration into host’s chromosomal DNA and without gradual loss from a dividing host cell also meaning that said vector replicates extrachromosomally or episomally.
- “Expression control sequences,” “control elements,” or “regulatory sequences” present in an expression vector are those non-translated regions of the vector including an origin of replication, selection cassettes, promoters, enhancers, translation initiation signals (Shine Dalgamo sequence or Kozak sequence) introns, a polyadenylation sequence, 5' and 3' untranslated regions, all of which interact with host cellular proteins to carry out transcription and translation.
- Such elements may vary in their strength and specificity.
- any number of suitable transcription and translation elements including ubiquitous promoters and inducible promoters may be used.
- a polynucleotide comprises a vector, including but not limited to expression vectors and viral vectors.
- a vector may comprise one or more exogenous, endogenous, or heterologous control sequences such as promoters and/or enhancers.
- An “endogenous control sequence” is one which is naturally linked with a given gene in the genome.
- An “exogenous control sequence” is one which is placed in juxtaposition to a gene by means of genetic manipulation (i.e., molecular biological techniques) such that transcription of that gene is directed by the linked enhancer/promoter.
- a “heterologous control sequence” is an exogenous sequence that is from a different species than the cell being genetically manipulated.
- a “synthetic” control sequence may comprise elements of one more endogenous and/or exogenous sequences, and/or sequences determined in vitro or in silico that provide optimal promoter and/or enhancer activity for the particular therapy.
- promoter refers to a recognition site of a polynucleotide (DNA or RNA) to which an RNA polymerase binds. An RNA polymerase initiates and transcribes polynucleotides operably linked to the promoter.
- promoters operative in mammalian cells comprise an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated and/or another sequence found 70 to 80 bases upstream from the start of transcription, a CNCAAT region where N may be any nucleotide.
- enhancer refers to a segment of DNA which contains sequences capable of providing enhanced transcription and in some instances can function independent of their orientation relative to another control sequence.
- An enhancer can function cooperatively or additively with promoters and/or other enhancer elements.
- promoter/enhancer refers to a segment of DNA which contains sequences capable of providing both promoter and enhancer functions.
- operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- the term refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, and/or enhancer) and a second polynucleotide sequence, e.g., a polynucleotide-of-interest, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
- constitutive expression control sequence refers to a promoter, enhancer, or promoter/enhancer that continually or continuously allows for transcription of an operably linked sequence.
- a constitutive expression control sequence may be a “ubiquitous” promoter, enhancer, or promoter/enhancer that allows expression in a wide variety of cell and tissue types or a “cell specific,” “cell type specific,” “cell lineage specific,” or “tissue specific” promoter, enhancer, or promoter/enhancer that allows expression in a restricted variety of cell and tissue types, respectively.
- Illustrative ubiquitous expression control sequences suitable for use in particular embodiments include, but are not limited to, a cytomegalovirus (CMV) immediate early promoter, a viral simian virus 40 (SV40) (e.g., early or late), a Moloney murine leukemia virus (MoMLY) LTR promoter, a Rous sarcoma virus (RSV) LTR, a herpes simplex virus (HSV) (thymidine kinase) promoter, H5, P7.5, and PI 1 promoters from vaccinia virus, an elongation factor 1 -alpha (EFla) promoter, early growth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock 70kDa protein 5 (HSPA5), heat shock protein 90kDa
- Ubiquitin C promoter Ubiquitin C promoter
- PGK phosphoglycerate kinase-1
- CAG cytomegalovirus enhancer/chicken b-actin
- MND myeloproliferative sarcoma virus enhancer
- a vector comprises an MNDU3 promoter.
- a vector comprises an EFla promoter comprising the first intron of the human EFla gene.
- a vector comprises an EFla promoter that lacks the first intron of the human EFla gene.
- a cell, cell type, cell lineage or tissue specific expression control sequence may be desirable to use to achieve cell type specific, lineage specific, or tissue specific expression of a desired polynucleotide sequence (e.g., to express a particular nucleic acid encoding a polypeptide in only a subset of cell types, cell lineages, or tissues or during specific stages of development).
- condition expression may refer to any type of conditional expression including, but not limited to, inducible expression; repressible expression; expression in cells or tissues having a particular physiological, biological, or disease state, etc. This definition is not intended to exclude cell type or tissue specific expression.
- Certain embodiments provide conditional expression of a polynucleotide-of-interest, e.g, expression is controlled by subjecting a cell, tissue, organism, etc., to a treatment or condition that causes the polynucleotide to be expressed or that causes an increase or decrease in expression of the polynucleotide encoded by the polynucleotide-of-interest.
- inducible prom oters/sy stems include, but are not limited to, steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionine promoter (inducible by treatment with various heavy metals), MX-1 promoter (inducible by interferon), the “GeneSwitch” mifepristone-regulatable system (Sirin et ah, 2003, Gene , 323:67), the cumate inducible gene switch (WO 2002/088346), tetracycline-dependent regulatory systems, etc.
- steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionine promoter (inducible by treatment with various heavy metals), MX-1 promoter (inducible by interferon), the “GeneS
- Inducer agents include, but are not limited to glucocorticoids, estrogens, mifepristone (RU486), metals, interferons, small molecules, cumate, tetracycline, doxycycline, and variants thereof.
- an “internal ribosome entry site” or “IRES” refers to an element that promotes direct internal ribosome entry to the initiation codon, such as ATG, of a cistron (a protein encoding region), thereby leading to the cap-independent translation of the gene. See, e.g., Jackson etal. , 1990. Trends Biochem Sci 15(12):477-83) and Jackson and Kaminski.
- RNA 1(10):985-1000 examples include those described in U.S. Pat. No. 6,692,736.
- IRES immunoglobulin heavy-chain binding protein
- VEGF vascular endothelial growth factor
- FGF-2 fibroblast growth factor 2
- IGFII insulin like growth factor
- eIF4G translational initiation factor eIF4G and yeast transcription factors TFIID and HAP4
- EMCV encephelomy carditis virus
- IRES have also been reported in viral genomes of Picomaviridae, Dicistroviridae and Flaviviridae species and in HCV, Friend murine leukemia virus (FrMLV) and Moloney murine leukemia virus (MoMLV).
- the IRES used in polynucleotides contemplated herein is an IRES used in polynucleotides contemplated herein.
- the polynucleot comprises a consensus Kozak sequence.
- Kozak sequence refers to a short nucleotide sequence that greatly facilitates the initial binding of mRNA to the small subunit of the ribosome and increases translation.
- the consensus Kozak sequence is (GCQRCCATGG (SEQ ID NO: 42), where R is a purine (A or G) (Kozak, 1986. Cell. 44(2):283-92, and Kozak, 1987. Nucleic Acids Res. 15(20):8125- 48).
- vectors comprise a polyadenylation sequence 3' of a polynucleotide encoding a polypeptide to be expressed.
- polyA site or “polyA sequence” as used herein denotes a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript by RNA polymerase P.
- Polyadenylation sequences can promote mRNA stability by addition of a polyA tail to the 3' end of the coding sequence and thus, contribute to increased translational efficiency.
- Cleavage and polyadenylation is directed by a poly(A) sequence in the RNA.
- the core poly(A) sequence for mammalian pre-mRNAs has two recognition elements flanking a cleavage-polyadenylation site. Typically, an almost invariant AAUAAA hexamer lies 20-50 nucleotides upstream of a more variable element rich in U or GU residues. Cleavage of the nascent transcript occurs between these two elements and is coupled to the addition of up to 250 adenosines to the 5' cleavage product.
- the core poly(A) sequence is an ideal polyA sequence (e.g ., AATAAA, ATTAAA, AGTAAA).
- the poly(A) sequence is an SV40 polyA sequence, a bovine growth hormone polyA sequence (BGHpA), a rabbit b-globin polyA sequence (rPgpA), variants thereof, or another suitable heterologous or endogenous polyA sequence known in the art.
- the poly(A) sequence is synthetic.
- polynucleotides encoding one or more polypeptides, or fusion polypeptides may be introduced into immune effector cells, e.g., T cells, by both non-viral and viral methods.
- delivery of one or more polynucleotides may be provided by the same method or by different methods, and/or by the same vector or by different vectors.
- vector is used herein to refer to a nucleic acid molecule capable transferring or transporting another nucleic acid molecule. The transferred nucleic acid is generally linked to, e.g., inserted into, the vector nucleic acid molecule.
- a vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into host cell DNA.
- non-viral vectors are used to deliver one or more polynucleotides contemplated herein to a T cell.
- non-viral vectors include, but are not limited to plasmids (e.g, DNA plasmids or RNA plasmids), transposons, cosmids, and bacterial artificial chromosomes.
- Illustrative methods of non-viral delivery of polynucleotides contemplated in particular embodiments include, but are not limited to: electroporation, sonoporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, nanoparticles, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, DEAE-dextran-mediated transfer, gene gun, and heat-shock.
- polynucleotide delivery systems suitable for use in particular embodiments contemplated in particular embodiments include, but are not limited to those provided by Amaxa Biosystems, Maxcyte, Inc., BTX Molecular Delivery Systems, and Copernicus Therapeutics Inc.
- Lipofection reagents are sold commercially (e.g, TransfectamTM and LipofectinTM). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides have been described in the literature. See e.g, Liu etal. (2003) Gene Therapy. 10:180-187; and Balazs etal. (2011) Journal of Drug Delivery. 2011:1-12.
- Antibody-targeted, bacterially derived, non-living nanocell-based delivery is also contemplated in particular embodiments.
- Viral vectors comprising polynucleotides contemplated in particular embodiments can be delivered in vivo by administration to an individual patient, typically by systemic administration (e.g, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application, as described below.
- vectors can be delivered to cells ex vivo , such as cells explanted from an individual patient (e.g, mobilized peripheral blood, lymphocytes, bone marrow aspirates, tissue biopsy, etc.) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient.
- viral vectors comprising polynucleotides contemplated herein are administered directly to an organism for transduction of cells in vivo.
- naked DNA can be administered.
- Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
- viral vector systems suitable for use in particular embodiments contemplated in particular embodiments include, but are not limited to, adeno- associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, and vaccinia virus vectors.
- AAV adeno-associated virus
- retrovirus retrovirus
- herpes simplex virus adenovirus
- vaccinia virus vectors vaccinia virus vectors.
- one or more polynucleotides encoding one or more DARJC components and/or other polypeptides contemplated herein are introduced into an immune effector cell, e.g., T cell, by transducing the cell with a recombinant adeno-associated virus (rAAV), comprising the one or more polynucleotides.
- an immune effector cell e.g., T cell
- rAAV recombinant adeno-associated virus
- AAV is a small ( ⁇ 26 nm) replication-defective, primarily episomal, non-enveloped virus. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell.
- Recombinant AAV rAAV
- rAAV are typically composed of, at a minimum, a transgene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs).
- the ITR sequences are about 145 bp in length.
- the rAAV comprises ITRs and capsid sequences isolated from AAVl, AAV2, AAV3,
- AAV4 AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10.
- a chimeric rAAV is used the ITR sequences are isolated from one AAV serotype and the capsid sequences are isolated from a different AAV serotype.
- a rAAV with ITR sequences derived from AAV2 and capsid sequences derived from AAV6 is referred to as AAV2/AAV6.
- the rAAV vector may comprise ITRs from AAV2, and capsid proteins from any one of AAVl, AAV2,
- the rAAV comprises ITR sequences derived from AAV2 and capsid sequences derived from AAV6. In a preferred embodiment, the rAAV comprises ITR sequences derived from AAV2 and capsid sequences derived from AAV2.
- engineering and selection methods can be applied to AAV capsids to make them more likely to transduce cells of interest.
- one or more polynucleotides encoding one or more DARIC components and/or other polypeptides contemplated herein are introduced into an immune effector cell, e.g, T cell, by transducing the cell with a retrovirus, e.g, lentivirus, comprising the one or more polynucleotides.
- an immune effector cell e.g, T cell
- a retrovirus e.g, lentivirus
- retrovirus refers to an RNA virus that reverse transcribes its genomic RNA into a linear double- stranded DNA copy and subsequently covalently integrates its genomic DNA into a host genome.
- retroviruses suitable for use in particular embodiments include, but are not limited to: Moloney murine leukemia virus (M- MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma Virus (RSV)) and lentivirus.
- M- MuLV Moloney murine leukemia virus
- MoMSV Moloney murine sarcoma virus
- Harvey murine sarcoma virus HaMuSV
- murine mammary tumor virus M
- lentivirus refers to a group (or genus) of complex retroviruses.
- Illustrative lentiviruses include, but are not limited to, HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna-maedi virus (VMV) virus; the caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
- HIV based vector backbones i.e ., HIV cis-acting sequence elements
- a lentiviral vector contemplated herein comprises one or more LTRs, and one or more, or all, of the following accessory elements: a cPPT/FLAP, a Psi (Y) packaging signal, an export element, poly (A) sequences, and may optionally comprise a WPRE or HPRE, an insulator element, a selectable marker, and a cell suicide gene, as discussed elsewhere herein.
- lentiviral vectors contemplated herein may be integrative or non-integrating or integration defective lentivirus.
- integration defective lentivirus or “IDLV” refers to a lentivirus having an integrase that lacks the capacity to integrate the viral genome into the genome of the host cells. Integration-incompetent viral vectors have been described in patent application WO 2006/010834, which is herein incorporated by reference in its entirety.
- HIV-1 pol gene suitable to reduce integrase activity include, but are not limited to: H12N, H12C, H16C, H16V, S81 R, D41A, K42A, H51A, Q53C, D55V, D64E, D64V, E69A, K71A, E85A, E87A, D116N, D1161, D116A, N120G, N1201, N120E, E152G, E152A, D35E, K156E, K156A, E157A, K159E, K159A, K160A, R166A, D167A, E170A, H171A, K173A, K186Q, K186T, K188T, E198A, R199c, R199T, R199A, D202A, K211A, Q214L, Q216L, Q221 L, W235F, W235E, K236S, K236A, K246A, G247W, D253
- LTR long terminal repeat
- FLAP element refers to a nucleic acid whose sequence includes the central polypurine tract and central termination sequences (cPPT and CTS) of a retrovirus, e.g., HIV-1 or HIV-2.
- cPPT and CTS central polypurine tract and central termination sequences
- Suitable FLAP elements are described in U.S. Pat. No. 6,682,907 and in Zennou, etal, 2000, Cell , 101:173.
- packaging signal or “packaging sequence” refers to psi [Y] sequences located within the retroviral genome which are required for insertion of the viral RNA into the viral capsid or particle, see e.g, Clever etal, 1995. ./. of Virology, Vol. 69, No.
- RNA export element refers to a cis-acting post-transcriptional regulatory element which regulates the transport of an RNA transcript from the nucleus to the cytoplasm of a cell.
- RNA export elements include, but are not limited to, the human immunodeficiency virus (HIV) rev response element (RRE) (see e.g, Cullen etal, 1991. J. Virol. 65: 1053; and Cullen etal, 1991. Cell 58: 423), and the hepatitis B vims post- transcriptional regulatory element (HPRE).
- HCV human immunodeficiency virus
- RRE hepatitis B vims post- transcriptional regulatory element
- expression of heterologous sequences in viral vectors is increased by incorporating posttranscriptional regulatory elements, efficient polyadenylation sites, and optionally, transcription termination signals into the vectors.
- posttranscriptional regulatory elements can increase expression of a heterologous nucleic acid at the protein, e.g., woodchuck hepatitis vims posttranscriptional regulatory element (WPRE; Zufferey etal. , 1999, ./. Virol., 73:2886); the posttranscriptional regulatory element present in hepatitis B vims (HPRE) (Huang el al, Mol. Cell. Biol., 5:3864); and the like (Liu el al, 1995, Genes Dev., 9:1766).
- WPRE woodchuck hepatitis vims posttranscriptional regulatory element
- HPRE posttranscriptional regulatory element present in hepatitis B vims
- Lentiviral vectors preferably contain several safety enhancements as a result of modifying the LTRs.
- Self-inactivating (SIN) vectors refers to replication-defective vectors, e.g, retroviral or lentiviral vectors, in which the right (3') LTR enhancer-promoter region, known as the U3 region, has been modified (e.g, by deletion or substitution) to prevent viral transcription beyond the first round of viral replication.
- Self-inactivation is preferably achieved through in the introduction of a deletion in the U3 region of the 3' LTR of the vector DNA, i.e., the DNA used to produce the vector RNA. Thus, during reverse transcription, this deletion is transferred to the 5' LTR of the proviral DNA.
- the U3 sequence it is desirable to eliminate enough of the U3 sequence to greatly diminish or abolish altogether the transcriptional activity of the LTR, thereby greatly diminishing or abolishing the production of full-length vector RNA in transduced cells.
- HIV based lentivectors it has been discovered that such vectors tolerate significant U3 deletions, including the removal of the LTR TATA box (e.g., deletions from -418 to -18), without significant reductions in vector titers.
- heterologous promoters which can be used include, for example, viral simian vims 40 (SV40) (e.g, early or late), cytomegalovims (CMV) (e.g, immediate early), Moloney murine leukemia vims (MoMLV), Rous sarcoma vims (RSV), and herpes simplex vims (HSV) (thymidine kinase) promoters.
- SV40 viral simian vims 40
- CMV cytomegalovims
- MoMLV Moloney murine leukemia vims
- RSV Rous sarcoma vims
- HSV herpes simplex vims
- HIV can be pseudotyped with vesicular stomatitis virus G-protein (VSV-G) envelope proteins, which allows HIV to infect a wider range of cells because HIV envelope proteins (encoded by the env gene) normally target the virus to CD4 + presenting cells.
- VSV-G vesicular stomatitis virus G-protein
- lentiviral vectors are produced according to known methods. See e.g., Kutner etal, BMC Biotechnol. 2009;9:10. doi: 10.1186/1472-6750-9-10; Kutner el al. Nat. Protoc. 2009;4(4):495-505. doi: 10.1038/nprot.2009.22.
- most or all of the viral vector backbone sequences are derived from a lentivirus, e.g., HIV-1.
- a lentivirus e.g., HIV-1.
- many different sources of retroviral and/or lentiviral sequences can be used, or combined and numerous substitutions and alterations in certain of the lentiviral sequences may be accommodated without impairing the ability of a transfer vector to perform the functions described herein.
- lentiviral vectors are known in the art, see Naldini etal, (1996a, 1996b, and 1998); Zufferey etal. , (1997); Dull etal. , 1998, U.S. Pat. Nos. 6,013,516; and 5,994,136, many of which may be adapted to produce a viral vector or transfer plasmid contemplated herein.
- one or more polynucleotides encoding one or more DARIC components and/or other polypeptides contemplated herein are introduced into an immune effector cell, by transducing the cell with an adenovirus comprising the one or more polynucleotides.
- Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Most adenovirus vectors are engineered such that a transgene replaces the Ad El a, Elb, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues in vivo , including non-dividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity.
- adenovirus vectors which are replication deficient, may utilize a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses El proteins (Graham et al ., 1977). Since the E3 region is dispensable from the adenovirus genome (Jones & Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the El, the D3 or both regions (Graham & Prevec, 1991). Adenovirus vectors have been used in eukaryotic gene expression (Levrero etal.
- one or more polynucleotides encoding one or more DARIC components and/or other polypeptides contemplated herein are introduced into an immune effector cell by transducing the cell with a herpes simplex virus, e.g., HSV-1, HSV-2, comprising the one or more polynucleotides.
- a herpes simplex virus e.g., HSV-1, HSV-2
- the mature HSV virion consists of an enveloped icosahedral capsid with a viral genome consisting of a linear double-stranded DNA molecule that is 152 kb.
- the HSV based viral vector is deficient in one or more essential or non-essential HSV genes.
- the HSV based viral vector is replication deficient. Most replication deficient HSV vectors contain a deletion to remove one or more intermediate-early, early, or late HSV genes to prevent replication.
- the HSV vector may be deficient in an immediate early gene selected from the group consisting of: ICP4, ICP22, ICP27, ICP47, and a combination thereof.
- HSV vectors are its ability to enter a latent stage that can result in long-term DNA expression and its large viral DNA genome that can accommodate exogenous DNA inserts of up to 25 kb.
- HSV-based vectors are described in, for example, U.S. Pat. Nos. 5,837,532, 5,846,782, and 5,804,413, and International Patent Applications WO 91/02788, WO 96/04394, WO 98/15637, and WO 99/06583, each of which are incorporated by reference herein in its entirety.
- cells are modified to express one or more DARICs, DARJC components, engineered TCRs, CARs, zetakines, and/or fusion proteins contemplated herein, for use in the treatment of cancer.
- Cells may be non-genetically modified to express one or more of the polypeptides contemplated herein, or in particular preferred embodiments, cells may be genetically modified to express one or more of the polypeptides contemplated herein.
- the term “genetically engineered” or “genetically modified” refers to the addition of extra genetic material in the form of DNA or RNA into the total genetic material in a cell.
- the terms, “genetically modified cells,” “modified cells,” and “redirected cells,” are used interchangeably in particular embodiments.
- one or more DARJC components that recruit a TCR complex are introduced and expressed in immune effector cells to improve the efficacy of the immune effector cells.
- one or more DARIC components that recruit a TCR complex are introduced and expressed in immune effector cells that have been redirected to a target cell by virtue of co-expressing an engineered antigen receptor, e.g., an engineered TCR, in the cell.
- a dual targeting immune effector cell where the target cell expresses a target antigen recognized by a DARIC and an MHC- antigen complex recognized by an TCR, e.g, an engineered TCR.
- a dual targeting immune effector cell where the target cell expresses CD33, CD123, CLL1, B7-H3, BCMA, CD19, CD20, CD22, CD79A, CD79B, EGFR, EGFRvIII, or an NKG2D ligand recognized by a DARIC receptor and a target antigen recognized by an engineered antigen receptor, e.g, an engineered TCR.
- an engineered antigen receptor e.g, an engineered TCR.
- an “immune effector cell,” is any cell of the immune system that has one or more effector functions (e.g, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and/or CDC).
- the illustrative immune effector cells contemplated herein are T lymphocytes, including but not limited to cytotoxic T cells (CTLs; CD8 + T cells), TILs, and helper T cells (HTLs; CD4 + T cells.
- the cells comprise ab T cells.
- the cells comprise gd T cells.
- immune effector cells include natural killer (NK) cells.
- immune effector cells include natural killer T (NKT) cells.
- Immune effector cells can be autologous/autogeneic (“self’) or non-autologous (“non-self,” e.g., allogeneic, syngeneic or xenogeneic).
- “Autologous,” as used herein, refers to cells from the same subject. “Allogeneic,” as used herein, refers to cells of the same species that differ genetically to the cell in comparison. “Syngeneic,” as used herein, refers to cells of a different subject that are genetically identical to the cell in comparison. “Xenogeneic,” as used herein, refers to cells of a different species to the cell in comparison. In preferred embodiments, the cells are human autologous immune effector cells.
- Illustrative immune effector cells suitable for introducing one or more DARIC components or a DARIC contemplated herein include T lymphocytes.
- T cell or “T lymphocyte” are art-recognized and are intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes.
- a T cell can be a T helper (Th) cell, for example a T helper 1 (Thl) or a T helper 2 (Th2) cell.
- the T cell can be a helper T cell (HTL; CD4 + T cell) CD4 + T cell, a cytotoxic T cell (CTL; CD8 + T cell), CD4 + CD8 + T cell, CD4 CD8- T cell, or any other subset of T cells.
- helper T cell HTL; CD4 + T cell
- CTL cytotoxic T cell
- CD4 + CD8 + T cell CD4 + CD8 + T cell
- CD4 CD8- T cell CD4 CD8- T cell
- immune effector cells comprising one or more DARIC components or a DARIC contemplated herein.
- immune effector cells also include NK cells, NKT cells, neutrophils, and macrophages.
- Immune effector cells also include progenitors of effector cells wherein such progenitor cells can be induced to differentiate into immune effector cells in vivo or in vitro.
- immune effector cells include progenitors of immune effectors cells such as hematopoietic stem cells (HSCs) contained within the CD34 + population of cells derived from cord blood, bone marrow or mobilized peripheral blood which upon administration in a subject differentiate into mature immune effector cells, or which can be induced in vitro to differentiate into mature immune effector cells.
- HSCs hematopoietic stem cells
- CD34 + cell refers to a cell expressing the CD34 protein on its cell surface.
- CD34 refers to a cell surface glycoprotein (e.g., sialomucin protein) that often acts as a cell-cell adhesion factor and is involved in T cell entrance into lymph nodes.
- the CD34 + cell population contains hematopoietic stem cells (HSC), which upon administration to a patient differentiate and contribute to all hematopoietic lineages, including T cells, NK cells, NKT cells, neutrophils and cells of the monocyte/macrophage lineage.
- HSC hematopoietic stem cells
- the method comprises transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells with one or more nucleic acids and/or vectors or combination thereof comprising one or more DARIC components contemplated herein.
- the method comprises transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells express one or more DARIC components and engineered antigen receptors contemplated herein.
- the immune effector cells are isolated from an individual and genetically modified without further manipulation in vitro. Such cells can then be directly re-administered into the individual.
- the immune effector cells are first activated and stimulated to proliferate in vitro prior to being genetically modified. In this regard, the immune effector cells may be cultured before and/or after being genetically modified.
- the source of cells is obtained from a subject.
- the modified immune effector cells comprise T cells.
- T cells can be obtained from a number of sources including, but not limited to, peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.
- T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled person, such as sedimentation, e.g., FICOLLTM separation.
- an isolated or purified population of T cells is used.
- both cytotoxic and helper T lymphocytes can be sorted into naive, memory, and effector T cell subpopulations either before or after activation, expansion, and/or genetic modification.
- an isolated or purified population of T cells expresses one or more of the markers including, but not limited to a CD3 + , CD4 + , CD8 + , or a combination thereof.
- the T cells are isolated from an individual and first activated and stimulated to proliferate in vitro prior to being modified to express one or more DARIC components.
- T cells are often subjected to one or more rounds of stimulation, activation and/or expansion.
- T cells can be activated and expanded generally using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; and 6,867,041, each of which is incorporated herein by reference in its entirety.
- T cells are activated and expanded for about 6 hours, about 12 hours, about 18 hours or about 24 hours prior to introduction of vectors or polynucleotides encoding one or more DARIC components, optionally in combination with an engineered antigen receptor contemplated herein.
- T cells are activated at the same time that they are modified.
- a method of generating an immune effector cell comprises activating a population of cells comprising T cells and expanding the population of T cells.
- T cell activation can be accomplished by providing a primary stimulation signal through the T cell TCR/CD3 complex and by providing a secondary costimulation signal through an accessory molecule, e.g, CD28.
- the TCR/CD3 complex may be stimulated by contacting the T cell with a suitable CD3 binding agent, e.g., a CD3 ligand or an anti-CD3 monoclonal antibody.
- a suitable CD3 binding agent e.g., a CD3 ligand or an anti-CD3 monoclonal antibody.
- CD3 antibodies include, but are not limited to, OKT3, G19-4, BC3, and 64.1.
- a CD28 binding agent can be used to provide a costimulatory signal.
- CD28 binding agents include but are not limited to: natural CD 28 ligands, e.g, a natural ligand for CD28 (e.g, a member of the B7 family of proteins, such as B7-1(CD80) and B7-2 (CD86); and anti-CD28 monoclonal antibody or fragment thereof capable of crosslinking the CD28 molecule, e.g, monoclonal antibodies 9.3, B-T3, XR-CD28, KOLT-2, 15E8, 248.23.2, and EX5.3D10.
- the molecule providing the primary stimulation signal for example a molecule which provides stimulation through the TCR/CD3 complex and the costimulatory molecule are coupled to the same surface.
- binding agents that provide stimulatory and costimulatory signals are localized on the surface of a cell. This can be accomplished by transfecting or transducing a cell with a nucleic acid encoding the binding agent in a form suitable for its expression on the cell surface or alternatively by coupling a binding agent to the cell surface.
- the molecule providing the primary stimulation signal for example a molecule which provides stimulation through the TCR/CD3 complex and the costimulatory molecule are displayed on antigen presenting cells.
- the molecule providing the primary stimulation signal for example a molecule which provides stimulation through the TCR/CD3 complex and the costimulatory molecule are provided on separate surfaces.
- one of the binding agents that provides stimulatory and costimulatory signals is soluble (provided in solution) and the other agent(s) is provided on one or more surfaces.
- the binding agents that provide stimulatory and costimulatory signals are both provided in a soluble form (provided in solution).
- the methods for making T cells contemplated herein comprise activating T cells with anti-CD3 and anti-CD28 antibodies.
- expanding T cells activated by the methods contemplated herein further comprises culturing a population of cells comprising T cells for several hours (about 3 hours) to about 7 days to about 28 days or any hourly integer value in between.
- the T cell composition may be cultured for 14 days.
- T cells are cultured for about 21 days.
- the T cell compositions are cultured for about 2-3 days. Several cycles of stimulation/activation/expansion may also be desired such that culture time of T cells can be 60 days or more.
- conditions appropriate for T cell culture include an appropriate media (e.g ., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15,
- an appropriate media e.g ., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15,
- IL-2 interleukin-2
- insulin IFN-g, IL-4, IL-7, IL-21, GM-CSF, IL-10, IL-12, IL-15, TGFP, and TNF-a or any other additives suitable for the growth of cells known to the skilled artisan.
- serum e.g., fetal bovine or human serum
- IL-2 interleukin-2
- insulin IFN-g, IL-4, IL-7, IL-21, GM-CSF, IL-10, IL-12, IL-15, TGFP, and TNF-a or any other additives suitable for the growth of cells known to the skilled artisan.
- cell culture media include, but are not limited to RPMI 1640, Clicks, AIM-V, DMEM, MEM, a-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells.
- Antibiotics e.g, penicillin and streptomycin
- the target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g, 37° C) and atmosphere (e.g, air plus 5% C02).
- PBMCs or isolated T cells are contacted with a stimulatory agent and costimulatory agent, such as anti-CD3 and anti-CD28 antibodies, generally attached to a bead or other surface, in a culture medium with appropriate cytokines, such as IL-2, IL-7, and/or IL-15.
- a stimulatory agent and costimulatory agent such as anti-CD3 and anti-CD28 antibodies
- cytokines such as IL-2, IL-7, and/or IL-15.
- artificial APC made by engineering K562, U937,
- K32 or U32 aAPCs are used to direct the display of one or more antibody-based stimulatory molecules on the AAPC cell surface.
- Populations of T cells can be expanded by aAPCs expressing a variety of costimulatory molecules including, but not limited to, CD137L (4-1BBL), CD134L (OX40L), and/or CD80 or CD86.
- the aAPCs provide an efficient platform to expand genetically modified T cells and to maintain CD28 expression on CD8 T cells.
- aAPCs provided in WO 03/057171 and US2003/0147869 are hereby incorporated by reference in their entirety.
- a polynucleotide encoding one or more DARIC components is introduced into the population of T cells.
- a polynucleotide encoding one or more DARIC components is introduced into a population of T cells that express an engineered antigen receptor.
- the polynucleotides may be introduced into the T cells by microinjection, transfection, lipofection, heat-shock, electroporation, transduction, gene gun, microinjection, DEAE-dextran-mediated transfer, and the like.
- polynucleotides are introduced into a T cell by viral transduction.
- viral vector systems suitable for introducing a polynucleotide into an immune effector cell or CD34 + cell include, but are not limited to adeno-associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, vaccinia vims vectors for gene transfer.
- AAV adeno-associated virus
- retrovirus retrovirus
- herpes simplex virus adenovirus
- vaccinia vims vectors for gene transfer include, but are not limited to adeno-associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, vaccinia vims vectors for gene transfer.
- polynucleotides are introduced into a T cell by AAV transduction.
- polynucleotides are introduced into a T cell by retroviral transduction.
- polynucleotides are introduced into a T cell by lentiviral transduction.
- polynucleotides are introduced into a T cell by adenovirus transduction.
- polynucleotides are introduced into a T cell by herpes simplex vims transduction.
- polynucleotides are introduced into a T cell by vaccinia vims transduction.
- compositions contemplated herein may comprise one or more DARIC polypeptides, polynucleotides encoding DARIC polypeptides, vectors comprising same, genetically modified immune effector cells, bridging factors, etc.
- Compositions include, but are not limited to, pharmaceutical compositions.
- a “pharmaceutical composition” refers to a composition formulated in pharmaceutically-acceptable or physiologically - acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy.
- compositions may be administered in combination with other agents as well, such as, e.g., cytokines, growth factors, hormones, small molecules, chemotherapeutics, pro-drugs, drugs, antibodies, or other various pharmaceutically-active agents.
- agents such as, e.g., cytokines, growth factors, hormones, small molecules, chemotherapeutics, pro-drugs, drugs, antibodies, or other various pharmaceutically-active agents.
- agents e.g., cytokines, growth factors, hormones, small molecules, chemotherapeutics, pro-drugs, drugs, antibodies, or other various pharmaceutically-active agents.
- additional agents do not adversely affect the ability of the composition to deliver the intended therapy.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier refers to a diluent, adjuvant, excipient, or vehicle with which the bridging factors, polypeptides, polynucleotides, vectors comprising same, or genetically modified immune effector cells are administered.
- pharmaceutical carriers can be sterile liquids, such as cell culture media, water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- a composition comprising a pharmaceutically acceptable carrier is suitable for administration to a subject.
- a composition comprising a carrier is suitable for parenteral administration, e.g ., intravascular (intravenous or intraarterial), intraperitoneal or intramuscular administration.
- a composition comprising a pharmaceutically acceptable carrier is suitable for intraventricular, intraspinal, or intrathecal administration.
- Pharmaceutically acceptable carriers include sterile aqueous solutions, cell culture media, or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the bridging factors, polypeptides, polynucleotides, vectors comprising same, or genetically modified immune effector cells, use thereof in the pharmaceutical compositions is contemplated.
- compositions contemplated herein comprise genetically modified T cells and a pharmaceutically acceptable carrier.
- a composition comprising a cell-based composition contemplated herein can be administered separately by enteral or parenteral administration methods or in combination with other suitable compounds to effect the desired treatment goals.
- compositions contemplated herein comprise a bridging factor and a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier must be of sufficiently high purity and of sufficiently low toxicity to render it suitable for administration to the human subject being treated. It further should maintain or increase the stability of the composition.
- the pharmaceutically acceptable carrier can be liquid or solid and is selected, with the planned manner of administration in mind, to provide for the desired bulk, consistency, etc., when combined with other components of the composition.
- the pharmaceutically acceptable carrier can be, without limitation, a binding agent (e.g, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.), a filler (e.g, lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates, calcium hydrogen phosphate, etc.), a lubricant (e.g ., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.), a disintegrant (e.g., starch, sodium starch glycolate, etc.), or a wetting agent (e.g, sodium lauryl sulfate, etc.).
- a binding agent e.g, pregelatinized maize starch, polyvinyl
- compositions contemplated herein include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatins, amyloses, magnesium stearates, talcs, silicic acids, viscous paraffins, hydroxymethylcelluloses, polyvinylpyrrolidones and the like.
- buffers refers to a solution or liquid whose chemical makeup neutralizes acids or bases without a significant change in pH.
- buffers contemplated herein include, but are not limited to, Dulbecco's phosphate buffered saline (PBS), Ringer's solution, 5% dextrose in water (D5W), normal/physiologic saline (0.9% NaCl).
- the pharmaceutically acceptable carriers may be present in amounts sufficient to maintain a pH of the composition of about 7.
- the composition has a pH in a range from about 6.8 to about 7.4, e.g, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, and 7.4.
- the composition has a pH of about 7.4.
- compositions contemplated herein may comprise a nontoxic pharmaceutically acceptable medium.
- the compositions may be a suspension.
- the term “suspension” as used herein refers to non-adherent conditions in which cells are not attached to a solid support. For example, cells maintained as a suspension may be stirred or agitated and are not adhered to a support, such as a culture dish.
- compositions contemplated herein are formulated in a suspension, where the modified T cells are dispersed within an acceptable liquid medium or solution, e.g, saline or serum-free medium, in an intravenous (IV) bag or the like.
- Acceptable diluents include, but are not limited to water, PlasmaLyte, Ringer's solution, isotonic sodium chloride (saline) solution, serum-free cell culture medium, and medium suitable for cryogenic storage, e.g, Cryostor® medium.
- a pharmaceutically acceptable carrier is substantially free of natural proteins of human or animal origin, and suitable for storing a composition comprising a population of modified T cells.
- the therapeutic composition is intended to be administered into a human patient, and thus is substantially free of cell culture components such as bovine serum albumin, horse serum, and fetal bovine serum.
- compositions are formulated in a pharmaceutically acceptable cell culture medium. Such compositions are suitable for administration to human subjects.
- the pharmaceutically acceptable cell culture medium is a serum free medium.
- Serum-free medium has several advantages over serum containing medium, including a simplified and better-defined composition, a reduced degree of contaminants, elimination of a potential source of infectious agents, and lower cost.
- the serum-free medium is animal-free, and may optionally be protein-free.
- the medium may contain biopharmaceutically acceptable recombinant proteins.
- “Animal-free” medium refers to medium wherein the components are derived from non-animal sources. Recombinant proteins replace native animal proteins in animal- free medium and the nutrients are obtained from synthetic, plant or microbial sources.
- Protein-free in contrast, is defined as substantially free of protein.
- serum-free media used in particular compositions includes, but is not limited to, QBSF-60 (Quality Biological, Inc.), StemPro-34 (Life Technologies), and X-VIVO 10.
- compositions comprising modified T cells are formulated in PlasmaLyte.
- compositions comprising modified T cells are formulated in a cryopreservation medium.
- cryopreservation media with cryopreservation agents may be used to maintain a high cell viability outcome post-thaw.
- cryopreservation media used in particular compositions includes, but is not limited to, CryoStor CS10, CryoStor CS5, and CryoStor CS2.
- the compositions are formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10.
- the composition is substantially free of mycoplasma, endotoxin, and microbial contamination.
- substantially free with respect to endotoxin is meant that there is less endotoxin per dose of cells than is allowed by the FDA for a biologic, which is a total endotoxin of 5 EU/kg body weight per day, which for an average 70 kg person is 350 EU per total dose of cells.
- compositions contemplated herein contain about 0.5 EU/mL to about 5.0 EU/mL, or about 0.5 EU/mL, 1.0 EU/mL, 1.5 EU/mL, 2.0 EU/mL, 2.5 EU/mL, 3.0 EU/mL, 3.5 EU/mL, 4.0 EU/mL, 4.5 EU/mL, or 5.0 EU/mL.
- formulation of pharmaceutically-acceptable carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g ., enteral and parenteral, e.g, intravascular, intravenous, intrarterial, intraosseously, intraventricular, intracerebral, intracranial, intraspinal, intrathecal, and intramedullary administration and formulation.
- enteral and parenteral e.g, intravascular, intravenous, intrarterial, intraosseously, intraventricular, intracerebral, intracranial, intraspinal, intrathecal, and intramedullary administration and formulation.
- enteral and parenteral e.g, intravascular, intravenous, intrarterial, intraosseously, intraventricular, intracerebral, intracranial, intraspinal, intrathecal, and intramedullary administration and formulation.
- particular embodiments contemplated herein may comprise
- compositions comprise an amount of immune effector cells that express one or more DARIC components contemplated herein.
- compositions comprise an amount of immune effector cells that express an engineered antigen receptor and one or more DARIC components contemplated herein.
- the term “amount” refers to “an amount effective” or “an effective amount” of cells comprising one or more DARIC components contemplated herein, etc., to achieve a beneficial or desired prophylactic or therapeutic result in the presence of a bridging factor, including clinical results.
- a “prophylactically effective amount” refers to an amount of cells comprising one or more DARIC components contemplated herein, etc., effective to achieve the desired prophylactic result in the presence of a bridging factor. Typically, but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount is less than the therapeutically effective amount.
- a “therapeutically effective amount” refers to an amount of cells comprising one or more DARIC components contemplated herein that is effective to “treat” a subject (e.g, a patient) in the presence of a bridging factor.
- a therapeutic amount is indicated, the precise amount of the compositions to be administered, cells, bridging factor, etc, can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject).
- a pharmaceutical composition comprising the immune effector cells described herein may be administered at a dosage of 10 2 to 10 10 cells/kg body weight, preferably 10 5 to 10 6 cells/kg body weight, including all integer values within those ranges.
- the number of cells will depend upon the ultimate use for which the composition is intended as will the type of cells included therein.
- the cells are generally in a volume of a liter or less, can be 500 mLs or less, even 250 mLs or 100 mLs or less.
- the density of the desired cells is typically greater than 10 6 cells/ml and generally is greater than 10 7 cells/ml, generally 10 8 cells/ml or greater.
- the clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , or 10 12 cells.
- lower numbers of cells in the range of 10 6 /kilogram (10 6 -10 u per patient) may be administered.
- the treatment may also include administration of mitogens (e.g, PHA) or lymphokines, cytokines, and/or chemokines (e.g, IFN-g, IL-2, IL-12, TNF-alpha, IL-18, and TNF-beta, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIRIa, etc.) as described herein to enhance induction of the immune response.
- mitogens e.g, PHA
- lymphokines e.g, lymphokines, cytokines, and/or chemokines (e.g, IFN-g, IL-2, IL-12, TNF-alpha, IL-18, and TNF-beta, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIRIa, etc.) as described herein to enhance induction of the immune response.
- chemokines e.g, IFN-g, IL-2,
- compositions comprising the cells activated and expanded as described herein may be utilized in the treatment and prevention of diseases that arise in individuals who are immunocompromised.
- compositions contemplated herein are used in the treatment of cancer.
- the immune effector cells may be administered either alone, or as a pharmaceutical composition in combination with carriers, diluents, excipients, and/or with other components such as IL-2 or other cytokines or cell populations.
- compositions comprise an amount of genetically modified T cells, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
- compositions comprise an amount of bridging factor, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
- compositions comprise an effective amount of immune effector cells comprising one or more DARIC components contemplated herein, alone or in combination with a bridging factor and/or one or more therapeutic agents, such as radiation therapy, chemotherapy, transplantation, immunotherapy, hormone therapy, photodynamic therapy, etc.
- therapeutic agents such as radiation therapy, chemotherapy, transplantation, immunotherapy, hormone therapy, photodynamic therapy, etc.
- the compositions may also be administered in combination with antibiotics.
- therapeutic agents may be accepted in the art as a standard treatment for a particular disease state as described herein, such as a particular cancer.
- Exemplary therapeutic agents contemplated include cytokines, growth factors, steroids, NSAIDs, DMARDs, anti inflammatories, chemotherapeutics, radiotherapeutics, therapeutic antibodies, or other active and ancillary agents.
- a composition comprising an effective amount of immune effector cells comprising one or more DARIC components contemplated herein is administered to a subject, and a composition comprising an effective amount of a bridging factor is administered to the subject, before, during, in combination with or subsequently to the cellular composition, and optionally repetitively administered to the subject.
- compositions comprising immune effector cells comprising one or more DARIC components contemplated herein may be administered in conjunction with any number of chemotherapeutic agents.
- the composition comprising immune effector cells comprising one or more DARIC components contemplated herein is administered with an anti-inflammatory agent.
- Anti-inflammatory agents or drugs include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti inflammatory drugs (NS AIDS) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate.
- steroids and glucocorticoids including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, pre
- DARIC components include but are not limited to, atezolizumab, avelumab, bavituximab, bevacizumab (avastin), bivatuzumab, blinatumomab, conatumumab, daratumumab, duligotumab, dacetuzumab, dalotuzumab, durvalumab, elotuzumab (HuLuc63), gemtuzumab, ibritumomab, indatuximab, inotuzumab, ipilimumab, lorvotuzumab, lucatumumab, milatuzumab, moxetumomab, nivolumab, ocaratuzumab, ofatumumab, pembrolizumab, rituxim
- compositions described herein are administered in conjunction with a cytokine.
- cytokine as used herein is meant a generic term for proteins released by one cell population that act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones.
- Immune effector cells modified to express a DARIC and/or an engineered antigen receptor contemplated herein provide improved methods of adoptive immunotherapy for use in the prevention, treatment, and amelioration of, or for preventing, treating, or ameliorating at least one symptom associated with an immune disorder, e.g., cancer.
- Immune effector cells comprising a DARIC signaling component that binds CD33, CD 123, CLL1, B7-H3, BMC A, CD 19, CD20, CD22, CD79A, CD79B, EGFR, EGFRvIII, or an NKG2D ligand and a DARIC binding component that binds CD3e, CD35 or CD3y, provide improved methods of adoptive immunotherapy for use in the prevention, treatment, and amelioration of, or for preventing, treating, or ameliorating at least one symptom associated with an immune disorder, e.g, cancer.
- an immune disorder e.g, cancer.
- Immune effector cells comprising a DARIC signaling component that binds CD33, CD 123, CLL1, B7-H3, BMC A, CD 19, CD20, CD22, CD79A, CD79B, EGFR, EGFRvIII, or an NKG2D ligand and a DARIC binding component that comprises a multimerization domain, a linker polypeptide, and CD3e, CD35 or CD3y, provide improved methods of adoptive immunotherapy for use in the prevention, treatment, and amelioration of, or for preventing, treating, or ameliorating at least one symptom associated with an immune disorder, e.g., cancer.
- an immune disorder e.g., cancer.
- immune effector cells modified to express a DARIC provide improved methods of adoptive immunotherapy to fine-tune the safety and efficacy of a cytotoxic response against target cells, e.g, tumor cells, expressing target antigens while decreasing the risk of on-target antigen, off-target cell cytotoxicity (recognizing the target antigen on a normal, non-target cell).
- target cells e.g, tumor cells, expressing target antigens while decreasing the risk of on-target antigen, off-target cell cytotoxicity (recognizing the target antigen on a normal, non-target cell).
- a method of preventing, treating, or ameliorating at least one symptom of a cancer comprises administering the subject an effective amount of modified immune effector cells or T cells comprising one or more components of a DARIC receptor and an engineered TCR, CAR, or other therapeutic transgene to redirect the cells to a target cell.
- the genetically modified cells are a more efficacious and safe cellular immunotherapy by virtue of transducing a chemically regulatable immunostimulatory signal.
- one or more immune effector cells are modified to express both a DARIC binding component and a DARIC signaling component.
- the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the signaling component expressed on the immune effector cell and the target antigen expressed on the target cell.
- a bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject.
- a complex forms between the DARIC signaling component bound to the target antigen, the bridging factor, and the DARIC binding component bound to a TCR complex.
- the DARIC transduces an immunostimulatory signal to the immune effector cell that synergizes with the TCR signal and in turn, elicits a cytotoxic response from the immune effector cell against the target cell.
- immune effector cells comprising a DARIC and/or an engineered antigen receptor fine-tune the safety and efficacy of a cytotoxic response against target cells using a dual targeting strategy wherein one or more target cells express one or more target antigens recognized by the engineered antigen receptor and the DARIC.
- one or more immune effector cells are modified to express both the DARIC binding component and the DARIC signaling component and an engineered antigen receptor, e.g, a TCR.
- the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the DARIC signaling component that binds a first target antigen and the TCR, which binds a second target antigen, wherein one or both target antigens are expressed on target cells or population of target cells. Interaction of the TCR with a target antigen on the target cell may elicit a cytotoxic response from the immune effector cell against the target cell.
- a bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject.
- a complex forms between the DARIC signaling component that binds a first target antigen, the bridging factor, and the DARIC binding component, which binds a TCR complex.
- the DARIC transduces an immunostimulatory signal to the immune effector cell that synergizes with the TCR signal and in turn, elicits or augments a cytotoxic response from the immune effector cell against the target cell.
- one or more immune effector cells are modified to express both a DARIC binding component and a DARIC signaling component.
- the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the signaling component expressed on the immune effector cell and the target antigen expressed on the target cell.
- a bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject.
- a complex forms between the DARIC signaling component bound to the target antigen, the bridging factor, and a DARIC binding component that comprises a multimerization domain, a linker polypeptide, and CD3e, CD35 or CD3y.
- the DARIC transduces an immunostimulatory signal to the immune effector cell that synergizes with the TCR signal and in turn, elicits a cytotoxic response from the immune effector cell against the target cell.
- one or more immune effector cells are modified to express both the DARIC binding component and the DARIC signaling component and an engineered antigen receptor, e.g, a TCR.
- the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the DARIC signaling component that binds a first target antigen and the TCR, which binds a second target antigen, wherein one or both target antigens are expressed on target cells or population of target cells. Interaction of the TCR with a target antigen on the target cell may elicit a cytotoxic response from the immune effector cell against the target cell.
- a bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject.
- a complex forms between the DARIC signaling component that binds a first target antigen, the bridging factor, and a DARIC binding component that comprises a multimerization domain, a linker polypeptide, and CD3e, CD35 or CD3y.
- the DARIC Upon formation of the complex, the DARIC transduces an immunostimulatory signal to the immune effector cell that synergizes with the TCR signal and in turn, elicits or augments a cytotoxic response from the immune effector cell against the target cell.
- the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers.
- the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, but not limited to: adrenal cancer, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain/CNS cancer, breast cancer, bronchial tumors, cardiac tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal carcinoma in situ (DCIS) endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing’s sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fallopian tube cancer, fibrous histiosarcoma, fibrosarcom
- the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, without limitation, non-small cell lung carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, and oligodendroglioma.
- the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, without limitation, non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.
- the modified immune effector cells contemplated herein are used in the treatment of glioblastoma
- the modified immune effector cells contemplated herein are used in the treatment of liquid cancers or hematological cancers.
- the modified immune effector cells contemplated herein are used in the treatment of B-cell malignancies, including but not limited to: leukemias, lymphomas, and multiple myeloma.
- the modified immune effector cells contemplated herein are used in the treatment of liquid cancers including, but not limited to leukemias, lymphomas, and multiple myelomas: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and polycythemia vera, Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, Burkitt lymphoma, small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymph
- ALL acute
- the modified immune effector cells contemplated herein are used in the treatment of acute myeloid leukemia (AML).
- AML acute myeloid leukemia
- Preferred cells for use in the methods contemplated herein include autologous/autogeneic (“self’) cells, preferably hematopoietic cells, more preferably T cells, and more preferably immune effector cells.
- self autologous/autogeneic
- a method comprises administering a therapeutically effective amount of modified immune effector cells that express one or more DARIC components, and optionally an engineered antigen receptor or another DARIC binding component, or a composition comprising the same, to a patient in need thereof, and also administering a bridging factor to the subject.
- the cells are used in the treatment of patients at risk for developing an immune disorder.
- particular embodiments comprise the treatment or prevention or amelioration of at least one symptom of an immune disorder, e.g., cancer, comprising administering to a subject in need thereof, a therapeutically effective amount of the modified immune effector cells contemplated herein and a bridging factor.
- modified immune effector cells DARIC binding components, and/or bridging factor
- the quantity and frequency of administration of modified immune effector cells, DARIC binding components, and/or bridging factor will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages and dose schedules may be determined by clinical trials.
- the effective amount of modified immune effector cells provided to a subject is at least 2 x 10 6 cells/kg, at least 3 x 10 6 cells/kg, at least 4 x 10 6 cells/kg, at least 5 x 10 6 cells/kg, at least 6 x 10 6 cells/kg, at least 7 x 10 6 cells/kg, at least 8 x 10 6 cells/kg, at least 9 x 10 6 cells/kg, or at least 10 x 10 6 cells/kg, or more cells/kg, including all intervening doses of cells.
- the effective amount of modified immune effector cells provided to a subject is about 2 x 10 6 cells/kg, about 3 x 10 6 cells/kg, about 4 x 10 6 cells/kg, about 5 x 10 6 cells/kg, about 6 x 10 6 cells/kg, about 7 x 10 6 cells/kg, about 8 x 10 6 cells/kg, about 9 x 10 6 cells/kg, or about 10 x 10 6 cells/kg, or more cells/kg, including all intervening doses of cells.
- the effective amount of modified immune effector cells provided to a subject is from about 2 x 10 6 cells/kg to about 10 x 10 6 cells/kg, about 3 x 10 6 cells/kg to about 10 x 10 6 cells/kg, about 4 x 10 6 cells/kg to about 10 x 10 6 cells/kg, about 5 x 10 6 cells/kg to about 10 x 10 6 cells/kg, 2 x 10 6 cells/kg to about 6 x 10 6 cells/kg, 2 x 10 6 cells/kg to about 7 x 10 6 cells/kg, 2 x 10 6 cells/kg to about 8 x 10 6 cells/kg, 3 x 10 6 cells/kg to about 6 x 10 6 cells/kg, 3 x 10 6 cells/kg to about 7 x 10 6 cells/kg, 3 x 10 6 cells/kg to about 8 x 10 6 cells/kg, 4 x 10 6 cells/kg to about 6 x 10 6 cells/kg, 4 x 10 6 cells/kg to about 6 x 10 6 cells/kg, 4 x 10 6 cells
- compositions contemplated in particular embodiments may be required to effect the desired therapy.
- a composition may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more times over a span of 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 5, years, 10 years, or more.
- Modified immune effector cells, DARIC components, and bridging factor may be administered in the same or different compositions; in one or more compositions at the same time; or more than one composition at different times.
- Modified immune effector cells, DARIC components, and bridging factor may be administered through the same route of administration or different routes.
- T cells can be activated from blood draws of from lOcc to 400cc.
- T cells are activated from blood draws of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, lOOcc, 150cc, 200cc, 250cc, 300cc, 350cc, or 400cc or more.
- using this multiple blood draw/multiple reinfusion protocol may serve to select out certain populations of T cells.
- a method of treating a subject diagnosed with a cancer comprises removing immune effector cells from the subject, modifying the immune effector cells by introducing one or more vectors encoding one or more DARIC components into the cell and producing a population of modified immune effector cells, and administering the population of modified immune effector cells to the same subject.
- the immune effector cells comprise T cells.
- a method of treating a subject diagnosed with a cancer comprises removing immune effector cells from the subject, modifying the immune effector cells by introducing one or more vectors encoding one or more DARIC components and optionally an engineered antigen receptor or another DARIC binding component into the cell and producing a population of modified immune effector cells, and administering the population of modified immune effector cells to the same subject.
- the immune effector cells comprise T cells.
- the methods for administering the cell compositions contemplated in particular embodiments include any method which is effective to result in reintroduction of ex vivo modified immune effector cells or reintroduction of modified progenitors of immune effector cells that upon introduction into a subject differentiate into mature immune effector cells.
- One method comprises modifying peripheral blood T cells ex vivo by introducing one or more vectors encoding one or more DARIC components and optionally an engineered antigen receptor or another DARIC binding component into the cell and returning the transduced cells into the subject.
- the methods for administering the cell compositions contemplated in particular embodiments include any method which is effective to result in reintroduction of ex vivo modified immune effector cells or reintroduction of modified progenitors of immune effector cells that upon introduction into a subject differentiate into mature immune effector cells.
- One method comprises modifying peripheral blood T cells ex vivo by introducing one or more vectors encoding one or more DARIC components and optionally an engineered antigen receptor or another DARIC binding component into the cell and returning the transduced cells into the subject.
- Figure 2 a CD8a-derived signal peptide, an FRB domain variant (T82L), a liner polypeptide, and CD3e, CD35, or CD3y
- P2A sequence a IgK-derived signal peptide, anti-CD 19 scFv, a FKBP12 domain, and a CD4 derived transmembrane and truncated intracellular domain were designed, constructed,
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962908082P | 2019-09-30 | 2019-09-30 | |
PCT/US2020/053388 WO2021067347A1 (en) | 2019-09-30 | 2020-09-30 | Dimerizing agent regulated immunoreceptor complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4038103A1 true EP4038103A1 (en) | 2022-08-10 |
Family
ID=75336478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20873077.0A Withdrawn EP4038103A1 (en) | 2019-09-30 | 2020-09-30 | Dimerizing agent regulated immunoreceptor complexes |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230031838A1 (en) |
EP (1) | EP4038103A1 (en) |
JP (1) | JP2022549514A (en) |
KR (1) | KR20220070501A (en) |
CN (1) | CN114616248A (en) |
AU (1) | AU2020359530A1 (en) |
CA (1) | CA3155027A1 (en) |
IL (1) | IL291743A (en) |
WO (1) | WO2021067347A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023196997A2 (en) * | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
CN115286697B (en) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | Dual-targeting compound and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10196444B2 (en) * | 2013-07-29 | 2019-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
EP3331913A1 (en) * | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
CN109311963A (en) * | 2016-04-14 | 2019-02-05 | 蓝鸟生物公司 | Succour Chimeric antigen receptor system |
-
2020
- 2020-09-30 KR KR1020227014102A patent/KR20220070501A/en unknown
- 2020-09-30 EP EP20873077.0A patent/EP4038103A1/en not_active Withdrawn
- 2020-09-30 JP JP2022519707A patent/JP2022549514A/en active Pending
- 2020-09-30 US US17/764,365 patent/US20230031838A1/en active Pending
- 2020-09-30 CA CA3155027A patent/CA3155027A1/en active Pending
- 2020-09-30 CN CN202080076045.0A patent/CN114616248A/en active Pending
- 2020-09-30 AU AU2020359530A patent/AU2020359530A1/en active Pending
- 2020-09-30 WO PCT/US2020/053388 patent/WO2021067347A1/en unknown
-
2022
- 2022-03-27 IL IL291743A patent/IL291743A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20230031838A1 (en) | 2023-02-02 |
JP2022549514A (en) | 2022-11-25 |
KR20220070501A (en) | 2022-05-31 |
CN114616248A (en) | 2022-06-10 |
CA3155027A1 (en) | 2021-04-08 |
AU2020359530A1 (en) | 2022-05-19 |
WO2021067347A1 (en) | 2021-04-08 |
IL291743A (en) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220031750A1 (en) | Dimerizing agent regulated immunoreceptor complexes | |
US20220025014A1 (en) | Dimerizing agent regulated immunoreceptor complexes | |
AU2018385694B2 (en) | NKG2D DARIC receptors | |
US20230031838A1 (en) | Dimerizing agent regulated immunoreceptor complexes | |
AU2020268379A1 (en) | CD33 targeted immunotherapies | |
WO2020227475A1 (en) | Cll-1 targeted immunotherapies | |
US20240025963A1 (en) | Dimerizing agent regulated immunoreceptor complexes | |
EP3723787A1 (en) | Daric interleukin receptors | |
US20240034768A1 (en) | Dimerizing agent regulated immunoreceptor complexes | |
WO2020227481A1 (en) | Cd123 targeted immunotherapies | |
WO2023196997A2 (en) | Multipartite receptor and signaling complexes | |
WO2022099176A1 (en) | Aml targeted immunotherapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220321 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40077779 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/725 20060101ALI20230809BHEP Ipc: A61K 39/00 20060101ALI20230809BHEP Ipc: A61K 31/711 20060101ALI20230809BHEP Ipc: A61K 31/7105 20060101ALI20230809BHEP Ipc: A61P 37/04 20060101ALI20230809BHEP Ipc: A61P 35/00 20060101ALI20230809BHEP Ipc: A61K 35/17 20150101ALI20230809BHEP Ipc: A61K 31/436 20060101ALI20230809BHEP Ipc: C07K 16/28 20060101AFI20230809BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20230929 |